Introduction {#s1}
============

Dysregulation of synaptic plasticity is implicated in cognitive and memory impairments associated with many neurological diseases and psychiatric disorders, such as Alzheimer's disease, schizophrenia, and intellectual disability. The AKT (Protein kinase B, PKB) signaling pathway is thought to play a pivotal role in synaptic plasticity ([@bib17]). AKT is a central serine/threonine kinase expressed in almost all cell types throughout the body and regulates cell growth, proliferation and metabolism. In post-mitotic neurons, the AKT pathway has significant functional impact on stress responses, neurotransmission and synaptic plasticity ([@bib37]).

Synaptic plasticity describes the specific modification of neuronal connections in response to neural activity. A persistent increase in synaptic strength after stimulation is known as long-term potentiation (LTP), while a decrease in synaptic strength is known as long-term depression (LTD). Late-phase LTP (L-LTP) is a long-lasting form of LTP that requires changes in gene expression and the synthesis of new proteins ([@bib46]). A form of LTD mediated by group one metabotropic glutamate receptors (mGluR-LTD) also requires protein synthesis ([@bib25]). Interestingly, AKT plays an important role in the mammalian target of rapamycin (mTOR) pathway controlling protein synthesis, and previous studies found that induction of L-LTP or mGluR-LTD in the hippocampus leads to AKT activation measured by increased phosphorylation of serine 473 ([@bib22]; [@bib21]).

AKT is known to include a family of three closely related isoforms, named AKT1, AKT2 and AKT3. Each isoform is encoded by a different gene, but the proteins share a high degree of structural homology ([@bib30]). Despite this homology, accumulating evidence suggests that each isoform is involved in distinct neurological disorders. Mutations in *AKT1* have been associated with schizophrenia, *AKT2* with gliomas and *AKT3* with brain growth ([@bib10]; [@bib55]; [@bib33]). Supporting these observations in humans, single-isoform *Akt* knockout (KO) mice also show distinct phenotypes. *Akt1* KO mice have growth retardation and increased neonatal death ([@bib9]; [@bib53]), *Akt2* KO mice suffer from a type two diabetes-like syndrome and *Akt3* KO mice show decreased brain size ([@bib9]; [@bib7]; [@bib48]). These data suggest that each isoform subserves different cellular functions to give rise to distinct phenotypes. Whether each AKT isoform plays different roles in synaptic plasticity has not been examined.

Activation of AKT has been correlated with LTP and LTD induction, implicating a role for AKT ([@bib22]; [@bib21]; [@bib36]). However, whether AKT activity is necessary in synaptic plasticity has not been directly tested. Moreover, all three AKT isoforms are present in the brain ([@bib9]). Given the numerous forms of synaptic plasticity, isoform-specific functions of AKT may provide an important mechanism for control and precision of the cellular processes supporting synaptic plasticity. Here, we show for the first time that each AKT isoform has a distinct expression pattern in the hippocampus. We then examined the role of each isoform in several hippocampal synaptic plasticity paradigms known to involve different molecular and cellular processes: early-phase LTP (E-LTP), L-LTP, low-frequency stimulation (LFS)-LTD, and mGluR-LTD. Our studies provide evidence that AKT isoforms play differential roles in synaptic plasticity due to cell-type-specific expression of *Akt* genes in the hippocampus and isoform-specific functions in protein synthesis.

Results {#s2}
=======

AKT isoforms show differential expression in the hippocampus {#s2-1}
------------------------------------------------------------

AKT is a well-studied kinase that may play a central role in brain disorders ([@bib17]). However, most studies examining AKT activity made no distinction between the activities of each isoform. We hypothesized that AKT isoforms play distinct roles in synaptic plasticity. To test this, we first examined the expression pattern of AKT1, AKT2 and AKT3 in the mouse hippocampus. We found that AKT1 and AKT3 were distributed throughout somatic layers of the hippocampus, with local differences in expression ([Figure 1](#fig1){ref-type="fig"}). AKT1 showed more intense immunoreactivity in the cell body layer of area CA1, whereas AKT3 showed more intense staining in cell bodies within area CA3 and the hilus of the dentate gyrus but reduced expression in the CA2/CA1 region. Interestingly, AKT2 showed a very different staining pattern. AKT2 was mostly expressed in cells of the molecular layer of the dentate gyrus and stratum radiatum of CA1 ([Figure 1](#fig1){ref-type="fig"}). Isoform-specific KO tissues confirmed specificity of the staining ([Figure 1](#fig1){ref-type="fig"}). Because the brain consists of neurons and glia cells, we next determined the cell types in which each isoform is expressed by co-staining brain slices for the neuronal marker neuron-specific nuclear protein (NeuN), the astrocytic marker glial fibrillary acidic protein (GFAP) and each AKT isoform. This triple stain approach revealed that within CA1, AKT1 was mainly expressed in pyramidal layer neurons, with no detectable staining in astrocytes ([Figure 2a,b](#fig2){ref-type="fig"}). Interestingly, certain neurons seemed to express more AKT1 compared with neighboring neurons ([Figure 2a,b](#fig2){ref-type="fig"}). In the CA1, AKT3 was also mainly expressed in neurons, including in the processes extending into stratum radiatum ([Figure 2a,b](#fig2){ref-type="fig"}). AKT2 showed no detectable co-localization with NeuN but co-localized with GFAP ([Figure 2a,b](#fig2){ref-type="fig"}). To confirm that AKT2 is not expressed in neurons, we employed a Cre-mediated strategy of selective *Akt2* gene disruption by crossing mice with floxed alleles of *Akt2* to three different mouse lines. Two of the lines have neuron-specific Cre recombinase expression (*Camk2α*-Cre and rat specific enolase, Nse or *Eno2*-Cre), while the third line expresses Cre recombinase in early neural progenitor cells that become astrocytes and neurons (*Nestin*-Cre \[[@bib47]\]). Using this strategy, we confirmed that AKT2 levels in the hippocampus were not affected by either neuron-specific Cre line, showing that *Akt2* is not likely to be expressed in hippocampal neurons ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). In contrast, the Nestin-Cre line completely abolished hippocampal AKT2 expression ([Figure 2---figure supplement 1b,c](#fig2s1){ref-type="fig"}), providing further support that AKT2 protein may be solely expressed in astrocytes and not in neurons of the hippocampus. Combined, our results demonstrate differential AKT isoform expression in the hippocampus. This isoform-specific expression may lead to unique functions of each isoform in synaptic plasticity processes.

![AKT isoform-specific expression in the hippocampus.\
Immunohistology using isoform-specific antibodies revealed distinct expression patterns for each AKT isoform in the hippocampus. AKT1 was mainly expressed in the cell body layers, with the greatest levels in stratum pyramidale of CA1. AKT2 was mostly expressed in specific cells in the molecular layer of the dentate gyrus, CA3 and CA1. AKT3 was also mainly expressed in the cell body layers of the hippocampus and showed strong expression in the hilus and CA3. Bottom panels show single *Akt* knockout (KO) tissue to validate the specificity of the antibodies.](elife-30640-fig1){#fig1}

![Cell-type-specific expression of AKT isoforms in hippocampal area CA1.\
(**a**). AKT1 was mainly expressed in neuronal cell bodies, indicated by co-localization with NeuN. Certain neurons in the pyramidal layer, stratum oriens and molecular layer showed greater expression levels of AKT1 (yellow arrows). AKT2 was specifically expressed in astrocytes, shown by co-localization with the astrocyte marker GFAP. AKT3 co-localized with NeuN like AKT1 but was also expressed in the stratum radiatum, most likely within dendrites. (**b**) Higher magnification showed no specific co-localization of AKT1 with GFAP and that certain neurons in the stratum oriens expressed high levels of AKT1 (yellow arrows). AKT2 was mainly expressed in the cell bodies of astrocytes. AKT3 showed high expression levels in neuronal cell bodies and dendrites and some expression in astrocytes.](elife-30640-fig2){#fig2}

AKT inhibition leads to reduced substrate activity and impaired L-LTP {#s2-2}
---------------------------------------------------------------------

AKT has been implicated in L-LTP ([@bib23]), but directly targeting AKT in L-LTP had not been studied. We chose to test the effects of two AKT inhibitors, AZD5363 (AZD) and MK2206-HCl (MK), on synaptic plasticity. AZD and MK have different mechanisms of action; AZD is an ATP-competitive AKT inhibitor ([@bib56]) and MK is an allosteric AKT inhibitor ([@bib35]). To examine AZD and MK action in the brain, we first assessed their effects on the phosphorylation of AKT and a well-characterized downstream target of AKT, glycogen synthase kinase 3β (GSK-3β) in hippocampal slices. Incubation with 10 µM MK strongly inhibited AKT activity as measured by the reduction of AKT phosphorylated on serine 473 (pAKT S473); however, phosphorylation levels of GSK-3β on serine 9 (pGSK-3β S9) were not reduced ([Figure 3a--c](#fig3){ref-type="fig"}). At higher doses of MK (30 µM and 100 µM), pAKT continued to be reduced at similar levels ([Figure 3a,b](#fig3){ref-type="fig"}), while pGSK-3β levels were ultimately reduced in a dose-dependent manner ([Figure 3a,c](#fig3){ref-type="fig"}). MK also reduced phosphorylation of another AKT target, tuberous sclerosis complex 2 on serine 939 (pTSC2 S939) ([@bib28]) but did not have a dose-dependent effect ([Figure 3a,d](#fig3){ref-type="fig"}). Additionally, we investigated the effect of MK on individual AKT isoforms and found that MK inhibits all isoforms, ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

![AKT inhibitors MK2206 and AZD5363 effectively inhibit AKT activity in hippocampal slices.\
(**a**) MK2206 and AZD5363 blocked AKT activity effectively, shown by reduced phosphorylation levels of the AKT substrate GSK-3β on serine 9 (pGSK-3β S9), but had different effects on phosphorylation levels of AKT itself on serine 473 (pAKT S473). (**b**) MK2206 (MK) significantly reduced pAKT S473 levels normalized to total AKT (totAKT) levels, while AZD5363 (AZD) significantly increased pAKT S473 levels (MK *F*~(3.8)~ = 30.93, p\<0.0001; AZD *F*~(3.8)~ = 12.30, p*=*0.0023). (**c**) MK had a dose-dependent effect on pGSK-3β S9 levels normalized to total GSK-3β (totGSK-3β) levels, with no effect at 10 µM but significantly reduced levels at 30 and 100 µM compared with vehicle treatment (MK *F*~(3,8)~=74.56, p\<0.001; post hoc comparisons: veh vs. MK10 p=0.998; veh vs. MK30 p=0.002; veh vs. MK100 p\<0.001, MK10 vs. MK30 p=0.002, MK30 vs. MK100 p\<0.001). AZD also had a dose-dependent effect on pGSK3β-S9 levels, with significant reduction at 10 µM in addition to the 30 and 100 µM doses compared with vehicle (AZD *F*~(3,8)~=39.69, p\<0.001; post hoc comparisons: veh vs. AZD10 p=0.002; veh vs. AZD30 p\<0.001; veh vs. AZD100 p\<0.001; AZD10 vs. AZD100 p=0.01). (**d**) MK and AZD treatment significantly reduced phosphorylation of TSC2 at serine 939 (pTSC2 S939) (MK *F*~(3,9)~=10.27, p=0.0041; AZD *F*~(3,9)~=7.893, p=0.0089). (**e**) Levels of GluA2 normalized to GAPDH was not significantly altered after MK or AZD treatment (MK *F*~(3,\ 8)~=0.279, p=0.838; AZD *F*~(3,9)~=0.378, p=0.771). Veh = vehicle, MK10 = 10 µM, MK30 = 30 µM, MK100 = 100 µM; AZD10 = 10 µM, AZD30 = 30 µM, AZD100 = 100 µM, 3--4 mice/group, \*p\<0.05.](elife-30640-fig3){#fig3}

Incubation of AZD, the other AKT inhibitor, resulted in increased pAKT levels collectively ([Figure 3a,b](#fig3){ref-type="fig"}) as well as individually for all three AKT isoforms ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Although seemingly paradoxical, this effect is consistent with previous reports that ATP-competitive inhibitors of AKT result in hyperphosphorylation of the kinase itself. The hyperphosphorylation does not indicate increased AKT activation but rather reflects intrinsic responses to competitive inhibition of AKT ([@bib38]). Previous studies have shown that binding of ATP-competitive AKT inhibitors results in translocation of AKT to the membrane where AKT is either more susceptible to phosphorylation ([@bib38]) or more resistant to dephosphorylation ([@bib6]), thereby leading to AKT hyperphosphorylation. To demonstrate that there is no feedback on upstream signals to compensate for AKT inhibition in brain slices, we examined phosphorylation of 3-phophoinositide-dependent protein kinase-1 (PDK1), a direct upstream activator of AKT, and found no effect of AZD on PDK1 activation ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). To confirm that AZD inhibited AKT activity despite the hyperphosphorylation of AKT, we examined AKT substrates and found significantly decreased phosphorylation levels of both GSK-3β, in a dose-dependent manner, and TSC2 ([Figure 3a,c,d](#fig3){ref-type="fig"}). Finally, the AKT1/2 inhibitor A6730 (10 mM) was recently found to reduce levels of the AMPA receptor subunit GluA2 ([@bib41]), but we found no reduction even with the highest concentration of AZD or MK ([Figure 3a,d](#fig3){ref-type="fig"}).

Based on the dose-response reduction of pGSK-3β S9 levels to AZD and MK, we chose to test 30 µM for both AKT inhibitors on synaptic plasticity in the CA3-CA1 circuit of the hippocampus. After determining that incubation of hippocampal slices from wild-type (WT) mice with either inhibitor did not affect the stability of baseline field excitatory postsynaptic potentials (fEPSP) recorded in CA1 up to 90 min after incubation ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we assessed the effect on expression of L-LTP induced by high-frequency stimulation (HFS). We found that both AKT inhibitors resulted in significantly impaired L-LTP compared with vehicle treatment ([Figure 4a,b](#fig4){ref-type="fig"}), indicating that AKT activity is required to sustain long-lasting LTP in area CA1.

![AKT inhibition and *Akt1* deletion results in impaired L-LTP.\
(**a**) Inhibiting AKT activity in hippocampal slices with AZD5363 (30 µM) prior to four trains of HFS (100 Hz) resulted in significantly impaired L-LTP in hippocampal area CA1 compared with vehicle treatment (*F*~(1,24)~=6.896, p=0.015), *n* = 13 slices/group, 5 mice/group. (**b**) AKT inhibitor MK2206 (30 µM) also significantly impaired L-LTP compared with vehicle treatment (*F*~(1,13)~=18.639, p\<0.001), *n* = 7--8 slices/group, 4 mice/group. (**c**) Western blot validation of AKT1, AKT2 and AKT3 removal using cortical tissue from *Akt* isoform-specific KO mice. β-actin, loading control. (**d**) *Akt1* KO mice showed significantly impaired L-LTP in hippocampal area CA1 compared with WT mice (*F*~(1,28)~=5.049, p=0.033), *n* = 15 slices/group, 6 mice/group. (**e**) *Akt2* KO mice displayed similar levels of L-LTP to WT mice (*F*~(1,20)~=1.121, p=0.302), *n* = 10--12 slices/group, 4--5 mice/group. (**f**) *Akt3* KO mice showed similar levels of L-LTP to WT mice (*F*~(1,20)~=0.33, p=0.857), *n* = 8--14 slices/group, 5--7 mice/group. \*p\<0.05.](elife-30640-fig4){#fig4}

Loss of AKT1 leads to impaired L-LTP {#s2-3}
------------------------------------

To determine if a specific AKT isoform was responsible for maintaining L-LTP in the CA3-CA1 circuit, we examined hippocampal slices from *Akt1*, *Akt2* or *Akt3* KO mice ([Figure 4c](#fig4){ref-type="fig"}). Because AKT has been linked to AMPA and NMDA receptor function ([@bib41]), we first examined the effect of deleting single *Akt* isoforms on basal synaptic transmission, presynaptic plasticity and short-term LTP in area CA1. We found normal synaptic input/output curves ([Figure 4---figure supplement 2a--c](#fig4s2){ref-type="fig"}), paired-pulse facilitation ([Figure 4---figure supplement 2d--f](#fig4s2){ref-type="fig"}) and E-LTP ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}) in all single *Akt* isoform mutants, suggesting no one isoform is required for normal basal synaptic transmission, presynaptic plasticity and short-term LTP. In contrast, we found that *Akt1* deletion resulted in impaired L-LTP ([Figure 4d](#fig4){ref-type="fig"}), while slices from *Akt2* or *Akt3* KO mice showed normal L-LTP ([Figure 4e,f](#fig4){ref-type="fig"}). To test if these mutant mice exhibit AKT isoform compensation, we examined the phosphorylation status of AKT3 in *Akt1* KO mice and, conversely, AKT1 in *Akt3* KO mice. We found no significant effect on pAKT3 in *Akt1* KO mice, while *Akt3* KO mice showed a small but significant increase in pAKT1 ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). This suggests that AKT3 is unable to compensate for AKT1 loss in L-LTP, resulting in impaired L-LTP in *Akt1* KO mice, while AKT1 may be able to compensate for AKT3 loss, allowing normal L-LTP in *Akt3* KO mice. Together, these results show that AKT1 is the major isoform involved in the expression of L-LTP and targeted by AZD and MK inhibition to impair L-LTP in CA1.

*Akt1* deletion results in impaired protein synthesis after L-LTP induction {#s2-4}
---------------------------------------------------------------------------

Hippocampal L-LTP requires synthesis of proteins that are involved in modifying synaptic connections ([@bib46]). Because the AKT pathway plays a well-known role in translational control, the AKT1 isoform may function in L-LTP by regulating protein synthesis. Interestingly, even though *Akt3* removal had no effect on L-LTP, *Akt3* KO mice have significantly smaller brains, which may indicate impaired translation. To examine protein synthesis associated with L-LTP in *Akt1* and *Akt3* KO hippocampal slices, we used the SuNSET method of labeling newly synthesized proteins ([@bib19]). Slices from *Akt1* or *Akt3* KO and WT littermates received either four spaced trains of HFS to induce L-LTP or no stimulation (control). Western blotting showed that *Akt1* KO slices failed to increase protein synthesis following L-LTP induction ([Figure 5a,c](#fig5){ref-type="fig"}), consistent with the L-LTP impairment observed in these slices ([Figure 4d](#fig4){ref-type="fig"}). In contrast, *Akt3* deletion did not affect the protein synthesis response post-HFS ([Figure 5b,d](#fig5){ref-type="fig"}), which is consistent with the normal L-LTP found in *Akt3* KO slices ([Figure 4f](#fig4){ref-type="fig"}). These results suggest an isoform-specific role for AKT1 in activity-induced protein synthesis that promotes L-LTP expression in the hippocampus.

![Only *Akt1* KO mice show an impaired protein synthesis response after tetanic stimulation.\
(**a,c**) Puromycin labeling of newly synthesized proteins showed that four trains of HFS in area CA1 to induce L-LTP results in increased protein synthesis levels compared with no stimulation (Ctrl) in WT hippocampal slices (*t~(14)~=* −3.52, p*=*0.005), while stimulated *Akt1* KO slices fail to increase protein synthesis from unstimulated levels (*t~(14)~=*-1.45, p*=*0.167). GAPDH, loading control. (**b,d**) *Akt3* KO hippocampal slices showed a normal increase in protein synthesis after four trains of HFS (*Akt3* WT Ctrl vs. HFS *t~(12)~=*-2.75, p*=*0.018; *Akt3* KO Ctrl vs. HFS *t = −*2.20, p*=*0.047). GAPDH, loading control. (**e,g**) *Akt1* KO slices failed to show an increase in S6 phosphorylation (pS6 S235/236) normalized to total S6 (totS6) levels after tetanic stimulation (*Akt1* WT Ctrl vs. HFS *t~(14)~=*-2.71, p*=*0.016; *Akt1* KO Ctrl vs. HFS *t~(14)~=*-1.01, p*=*0.33). (**f,h**) *Akt3* KO slices showed a normal increase in pS6 S235/236 levels after tetanic stimulation (*Akt3* WT Ctrl vs. HFS *t~(14)~=*-2.92, p*=*0.01, *Akt3* KO Ctrl vs. HFS *t~(14)~=*-2.59, p*=*0.02). *n*= 7--11 slices/group, 4--6 mice/group, \*p\<0.05.](elife-30640-fig5){#fig5}

To investigate the molecular signaling pathways linking AKT activity to translational control in long-lasting synaptic plasticity, we examined the phosphorylation levels of a well-known AKT effector, S6. S6 is a component of the 40S ribosomal subunit that mediates translation, and phosphorylation of S6 at serine 235 and 236 (pS6) is essential for S6 cap-binding activity ([@bib27]). We found that pS6 levels significantly increased after tetanic stimulation in WT and *Akt3* KO hippocampal slices but not in *Akt1* KO slices ([Figure 5e--h](#fig5){ref-type="fig"}). This result agrees with the impaired protein synthesis after tetanic stimulation observed with AKT1 deficiency. Therefore, AKT1 is the critical isoform supporting hippocampal L-LTP through activity-regulated signaling to protein synthesis and may compensate for AKT3 to enable normal L-LTP and associated protein synthesis in *Akt3* KO conditions.

AKT activity is not required for LTD induced by low-frequency stimulation {#s2-5}
-------------------------------------------------------------------------

Another form of synaptic plasticity is LTD induced by low-frequency stimulation (LFS-LTD), which is known to depend on NMDA receptor-mediated calcium influx and is independent of protein synthesis ([@bib25]). Previously, synaptic plasticity related to brain-derived neurotrophic factor signaling was reported to involve a feedforward AKT mechanism to NMDA receptors ([@bib36]). Furthermore, the AKT substrate GSK-3β was found to be important for LFS-LTD, and phosphorylation levels of GSK-3β was found to be reduced in *Akt3* KO brains ([@bib40]; [@bib4]). We confirmed that *Akt3* deletion results in decreased hippocampal levels of pGSK-3β ([Figure 6a](#fig6){ref-type="fig"}). In contrast, *Akt1* KO mice show normal pGSK-3β levels ([Figure 6a](#fig6){ref-type="fig"}), revealing further differential AKT isoform signaling. Therefore, AKT activity, especially AKT3, may be involved in maintaining LFS-LTD. To address this question, we examined LFS-LTD in the CA3-CA1 circuit of single *Akt* isoform mutant slices and found no effect of any single isoform deletion ([Figure 6b--d](#fig6){ref-type="fig"}). To determine if these findings resulted from incomplete blockade of AKT activity or if multiple isoforms are involved, we examined LFS-LTD in WT hippocampal slices following pharmacological inhibition of AKT activity using AZD or MK. We found normal expression of LFS-LTD compared to vehicle-treated slices ([Figure 6e,f](#fig6){ref-type="fig"}). Therefore, these experiments combined indicate that AKT is not required for LFS-LTD in CA1.

![AKT is not involved in LFS-LTD.\
(**a**) pGSK-3β levels were significantly reduced in the hippocampus of *Akt3* KO mice but normal in *Akt1* KO mice (*Akt3* KO *t~(20)~=*-4.725, p\<0.001; *Akt1* KO *t~(14)~=*0.104, p=0.918), 4--6 mice/group. (**b--d**) Hippocampal slices from *Akt1* KO, *Akt2* KO or *Akt3* KO mice showed normal LFS-LTD induced by 900 stimuli of 1 Hz compared to WT slices (p\>0.05 for all genotypes), *n* = 12--20 slices/group, 5--7 mice/group. (**e**) Blocking AKT activity in hippocampal slices with AZD5363 (30 µM) prior to 900 stimuli of 1 Hz did not affect LFS-LTD compared to vehicle-treated slices (p\>0.05), *n* = 12--13 slices/group, 6 mice/group. (**f**) AKT activity blocked by MK2206 (30 µM) also resulted in normal LFS-LTD in hippocampal slices compared to vehicle-treated slices (p\>0.05), *n* = 10--12 slices/group, 5 mice/group.](elife-30640-fig6){#fig6}

Inhibition of AKT activity leads to enhanced mGluR-LTD {#s2-6}
------------------------------------------------------

Previous studies suggest AKT is involved in another form of LTD, which is mediated by mGluR (mGluR-LTD) and depends on protein synthesis ([@bib26]). Upon mGluR stimulation with DHPG, pAKT S473 levels were shown to increase, suggesting increased AKT activity ([@bib22]). Also, inhibiting phosphoinositide 3-kinase (PI3K) activity, a well-validated kinase upstream of AKT activation ([@bib12]), results in impaired mGluR-LTD ([@bib22]). However, direct interrogation of the role of AKT in mGluR-LTD expression had never been performed. Thus, we directly examined AKT function in mGluR-LTD using the pan-AKT inhibitors AZD and MK and *Akt* mutants.

We incubated WT hippocampal slices with AKT inhibitors prior to mGluR-LTD induction with DHPG ([@bib29]). Unexpectedly, we found that inhibiting AKT activity with either AZD or MK enhanced mGluR-LTD ([Figure 7a,b](#fig7){ref-type="fig"}). Because a previous report using LY294002 inhibition of PI3K, a major upstream activator of AKT ([@bib52]), showed impaired mGluR-LTD ([@bib22]), we had expected to find that direct AKT inhibition also would impair mGluR-LTD ([@bib22]). We therefore repeated the experiment with LY294002. In agreement with our MK and AZD data, we found that inhibition of PI3K resulted in enhanced mGluR-LTD ([Figure 7c](#fig7){ref-type="fig"}). These results demonstrate that AKT is indeed involved in regulating mGluR-LTD, although in a different manner than we expected.

![Blocking AKT activity leads to enhanced mGluR-LTD.\
(**a,b**) Blocking AKT activity using AZD5363 or MK2206 resulted in enhanced mGluR-LTD induced with 3,5 RS-DHPG (100 µM) in hippocampal area CA1 (AZD *F*~(1,23)~=5.010, p=0.035; MK *F*~(1,40)~=7.216, p=0.010), *n* = 12--20 slices/group, 5--6 mice/group. (**c**) Blocking PI3K using LY294002 resulted in enhanced mGluR-LTD (*F*~(1,27)~=10.809, p=0.003), *n* = 13--16 slices/group, 7--8 mice/group. (**d--f**) *Akt1, Akt2* or *Akt3* KO mice show normal mGluR-LTD compared to WT controls (p\>0.05), *n* = 13--20 slices/group, 5--7 mice/group. \*p\<0.05.](elife-30640-fig7){#fig7}

To investigate isoform-specific contributions to this phenotype, we next induced mGluR-LTD in *Akt1*, *Akt2* or *Akt3* KO hippocampal slices. Interestingly, we found that all single isoform mutant slices displayed normal mGluR-LTD ([Figure 7d--f](#fig7){ref-type="fig"}). Because pan-AKT and PI3K inhibition both resulted in enhanced mGluR-LTD ([Figure 7a--c](#fig7){ref-type="fig"}), two or more isoforms may redundantly compensate for each other to allow normal expression of mGluR-LTD in the single *Akt* isoform mutants. To test this idea, we generated multiply mutant *Akt* mice.

*Akt1*/*Akt3* double mutants have enhanced mGluR-LTD {#s2-7}
----------------------------------------------------

Because *Akt1* and *Akt3* are the more similarly expressed isoforms in the hippocampus, we hypothesized that AKT1 and AKT3 may substitute for each other in regulating mGluR-LTD expression at CA3-CA1 synapses. Therefore, combined *Akt1* and *Akt3* deletion may result in enhanced mGluR-LTD, reproducing the effect of pan-AKT inhibition with either AZD or MK. Because *Akt1*/*Akt3* double KO mice are embryonic lethal ([@bib53]), we used a Cre-mediated strategy of selective *Akt1* disruption by crossing mice with floxed alleles of *Akt1* to a forebrain-specific neuronal Cre recombinase mouse line (T29) in an *Akt3* KO background (cA1F/A3K mice) ([Figure 8a](#fig8){ref-type="fig"}). Using this strategy, AKT3 is removed and AKT1 levels are significantly reduced in the hippocampus of cA1F/A3K mice compared with WT mice ([Figure 8b,c](#fig8){ref-type="fig"}). Immunostaining of the hippocampus showed *Akt1* was mostly deleted from excitatory pyramidal neurons in area CA1, while other neurons, most likely inhibitory neurons, still expressed AKT1 ([Figure 8d](#fig8){ref-type="fig"}). Next, we examined mGluR-LTD in cA1F/A3K mice. Consistent with our results from the AKT inhibitor experiments, we found that mGluR-LTD was enhanced in cA1F/A3K mice compared with WT mice ([Figure 8e](#fig8){ref-type="fig"}). Thus, concomitant *Akt1* and *Akt3* deletion results in enhanced mGluR-LTD, supporting the idea that the AKT1 and AKT3 isoforms function in hippocampal mGluR-LTD and can compensate for each other.

![AKT1 and AKT3 are involved in mGluR-LTD.\
(**a**) Double *Akt1* and *Akt3* mutant (cA1F/A3K) mice with Cre-mediated removal of both *Akt1* alleles in the *Akt3* KO background were generated with WT littermate controls by breeding *Camk2a-Cre::Akt1^loxP/+^*/*Akt3^+/-^* female mice with *Akt1^loxP/+^*/*Akt3^+/-^* males. (**b,c**) Western blot analysis showing significantly reduced AKT1 levels and no AKT3 expression in the hippocampus of cA1F/A3K mice compared with WT mice (AKT1 levels: *t~(6)~*=3.802, p=0.008). (**d**) Immunostaining confirming reduced neuronal AKT1 expression by *Camk2a*-driven Cre removal of *Akt1* in the hippocampus, especially in the pyramidal cell body layer of CA1. (**e**) mGluR-LTD is enhanced in cA1F/A3K hippocampal slices (*F*~(1,30)~=7.923, p=0.009), *n* = 16 slices/group, 5 mice/group. (**f,g**) Western blot analysis showing significantly increased phosphorylation of ERK Thr202/Tyr204 and S6 S235/236 but not TSC2 S939 in cA1F/A3K hippocampal slices at 60 min post-DHPG, while WT slices had no differences (pERK: WT Ctrl vs. DHPG *t~(22)~=*1.814, p*=*0.083, cA1F/A3K Ctrl vs. DHPG *t~(14)~=*2.918, p*=*0.011; pS6: WT Ctrl vs. DHPG *t~(22)~=*1.252, p*=*0.224, cA1F/A3K Ctrl vs. DHPG *t~(14)~=*2.647, p*=*0.019; pTSC2: WT Ctrl vs. DHPG *t~(20)~=*1.252, p*=*0.225, cA1F/A3K Ctrl vs. DHPG *t~(14)~=*0.374, p*=*0.714). *n*= 8--12 slices/group, 4--6 mice/group, \*p\<0.05.](elife-30640-fig8){#fig8}

To investigate the signaling pathways underlying this mGluR-LTD enhancement, we next examined the activity of several proteins known to be involved in mGluR-LTD: extracellular regulated kinase (ERK) ([@bib14]), ribosomal protein S6 ([@bib1]), and TSC2 ([@bib3]). At 60 min post-DHPG, when cA1F/A3K slices show enhanced mGluR-LTD, we found that phosphorylation levels of ERK and S6 were not different in DHPG-treated WT slices but significantly increased in DHPG-treated cA1F/A3K slices compared with vehicle treatment. In contrast, phosphorylation of TSC2 showed no difference in either WT or cA1F/A3K slices 60 min post-DHPG compared to vehicle treatment. Interestingly, however, basal levels of TSC2 phosphorylation were significantly reduced in cA1FA3K slices compared with WT slices ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Together, these results show that removal of both AKT1 and AKT3 isoforms leads to altered ERK and S6 activity regulation, which then most likely leads to enhanced synaptic depression upon mGluR1 stimulation.

Discussion {#s3}
==========

Our studies discovered novel distinct roles for the different *Akt* isoforms in the brain. We show, for the first time, that AKT2 expression is localized to astrocytes in the hippocampus, while AKT1 and AKT3 are primarily but differentially expressed in neurons. We also show for the first time that these differences in isoform expression are associated with different functions in the brain involving synaptic plasticity. We demonstrate that the AKT1 isoform is critical for the expression of L-LTP and regulating activity-induced protein synthesis that supports L-LTP in area CA1. Interestingly, in contrast to the apparent singular requirement for AKT1 in L-LTP, we found that AKT1 and AKT3 serve overlapping roles to inhibit the expression of mGluR-LTD in area CA1. To our knowledge, this is the first study to identify AKT isoform-specific expression in the hippocampus and AKT isoform-specific activity underlying different forms of hippocampal synaptic plasticity.

Because AKT controls numerous cellular processes, uncovering isoform differences is important to improve understanding about normal AKT function. Moreover, isoform-specific roles for AKT have been associated with different disease pathologies. The AKT2 isoform, for example, has been implicated in diabetes. A missense mutation in *AKT2* that causes loss of AKT2 function leading to insulin resistance was identified in a family with diabetes ([@bib15]). Similarly, AKT2-deficient mice have resistance to insulin and a subset develop diabetes-mellitus-like syndrome ([@bib7]). AKT2 also has been associated with glioma, a type of brain cancer with malignant tumors derived from glial cells. High-grade gliomas have been shown to overexpress AKT2 ([@bib55]). Although this correlation suggests a role for AKT2 in astrocytic function, we were surprised that our immunostaining in the hippocampus showed AKT2 to be present predominantly in astrocytes. Cre recombinase under the nestin promoter in neural progenitor cells, which generate both neurons and astrocytes, completely ablated AKT2 in the hippocampus ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}), whereas neuron-restricted Cre recombinase had no effect on hippocampal AKT2 levels ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). Deducing from these results suggests that AKT2 is only expressed in astrocytes. However, it may be that our strategies have limited sensitivity to detect trace amounts of AKT2 in neurons. Expression data from other studies also do not provide conclusive answers to where AKT2 is expressed in the brain. For example, the Allen Brain Atlas shows *Akt2* mRNA expression to be merely neuronal, whereas single-cell RNA sequencing of hippocampal cells identified *Akt2* only in astrocytes ([@bib54]). In a proteome analysis of the brain, expression of all three AKT isoforms were reported in all brain cell types in almost equal amounts ([@bib44]). Although these methods generate large amounts of data and are important to examine the transcriptome on a large scale, these studies have not specifically verified AKT isoform expression in more depth. Close examination of our immunostaining revealed little or no detectable AKT1 and AKT3 expression in astrocytes ([Figure 2](#fig2){ref-type="fig"}), although we cannot exclude that they may be present. Therefore, it may be possible that AKT2 expression is restricted to hippocampal astrocytes or becomes restricted post-developmentally or that signals from other brain cell types in vivo restrict AKT2 expression to astrocytes. Although we found no evidence of a role for AKT2 in the synaptic plasticity paradigms tested in this study, AKT2 might play a role in synaptic plasticity as it relates to astrocytic function for supporting neuronal activity ([@bib39]).

The AKT1 isoform specifically has been linked to schizophrenia, a neurological disorder believed to represent brain dysconnectivity with a molecular basis in aberrant synaptic plasticity ([@bib45]). AKT1 is one of the effectors in the well-established pathway from neuregulin 1 (*NRG1-ERBB4-PI3K-AKT1* pathway), where each of these components have genetic polymorphisms that have been linked to schizophrenia ([@bib10]; [@bib16]). These polymorphisms may lead to lower AKT1 protein levels in schizophrenia ([@bib10]; [@bib49]), although increased AKT1 expression and activity also have been reported in schizophrenia ([@bib18]; [@bib31]). Human olfactory neurosphere-derived cells collected from schizophrenia patients were shown to have reduced protein synthesis ([@bib11]). Additionally, the antipsychotic haloperidol used to treat schizophrenia can activate the AKT pathway, thereby inducing protein synthesis ([@bib5]). Together, these reports may suggest protein synthesis is reduced in schizophrenia, which may be due to reduced AKT1 signaling. Because protein synthesis is crucial to maintain L-LTP ([@bib46]), our finding that *Akt1* deletion results in the impairment of L-LTP ([Figure 4](#fig4){ref-type="fig"}) and the associated protein synthesis response ([Figure 5](#fig5){ref-type="fig"}) suggests AKT1 may be an important factor in the synaptic and cognitive deficits observed in schizophrenia ([@bib45]).

The AKT3 isoform is expressed in a highly overlapping pattern with AKT1 in the hippocampus ([Figure 1](#fig1){ref-type="fig"}), suggesting overlapping roles with AKT1, but there are also notable differences between their expression. For example, AKT3 shows expression in the neuropil ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). AKT3 is known to control brain size ([@bib9]; [@bib48]). Mutations that result in enhanced AKT3 activity lead to increased brain growth ([@bib33]), while deletion of *AKT3* is involved in microcephaly ([@bib13]). AKT3 may control brain growth through regulation of protein synthesis. Deletion of *Akt3* is known to reduce phosphorylation of the ribosomal protein S6 ([@bib9]), which is an effector in the AKT-mTOR pathway leading to protein synthesis. Intriguingly, our results show that only AKT1-deficient mice display impaired protein synthesis-dependent L-LTP, while deletion of *Akt3* has no effect ([Figure 4](#fig4){ref-type="fig"}). These data are consistent with the idea that while both AKT1 and AKT3 can regulate neuronal protein synthesis, AKT1 is specifically recruited to support translation involved in L-LTP.

What mechanisms might underlie the differential regulation of protein synthesis by AKT1 and AKT3? Phosphorylation of S6 on S235/236 is increased after L-LTP, which correlates with increased translation ([@bib2]). Consistent with our finding that *Akt1* deletion leads to an impaired protein synthesis response, *Akt1* KO slices fail to increase S6 phosphorylation following stimulation, whereas *Akt3* KO slices still display dynamic range in protein synthesis and S6 activation ([Figure 5](#fig5){ref-type="fig"}). Noteworthy, previously it was found that basal phosphorylation of S6 is reduced in *Akt3* KO mice but not in *Akt1* KO mice ([@bib9]), which we were able to confirm ([Figure 5e,f](#fig5){ref-type="fig"}). These results show distinct roles for AKT1- and AKT3-mediated protein synthesis. AKT1 is the activity-regulated isoform, converting external stimuli into protein synthesis, while AKT3 may be more important for steady-state protein synthesis. This distinction may also correlate with the regional differences we observed in hippocampal AKT1 and AKT3 expression ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Thus, in regions where AKT3 expression predominates like area CA3, *Akt3* KO slices may show altered activity-induced protein synthesis, following stimulation of the mossy fiber-CA3 circuit for instance. Additionally, future experiments aimed at finer localization of AKT1 and AKT3 may help to answer this question.

mGluR-LTD has been widely studied in relation to the neurodevelopmental disorder fragile X syndrome (FXS) and shown to be enhanced in hippocampal slices from *Fmr1* KO mice, a mouse model of FXS ([@bib24]). mGluR-LTD requires protein synthesis, leading to AMPA receptor internalization ([@bib26]). AKT has been implicated in the cascade mediating this protein synthesis after mGluR stimulation ([@bib22]). Studies inhibiting upstream and downstream signaling of AKT have suggested that mGluR stimulation activates a cascade through PI3K-AKT-TSC-mTORC1-S6K to protein synthesis. However, there are conflicting findings about the role of this signaling cascade in mGluR-LTD. In support of the idea that AKT functions in this pathway to facilitate mGluR-LTD, pharmacological studies inhibiting PI3K ([@bib22]; [@bib42]) or mTORC1 ([@bib42]; [@bib43]) have reported mGluR-LTD impairment. On the other hand, inhibiting mTORC1 also has been reported to have no effect on mGluR-LTD ([@bib3]; [@bib42]). Likewise, loss of S6K1 has been shown to have no effect on mGluR-LTD, while S6K2 loss results in enhanced mGluR-LTD ([@bib1]). Some of these divergent results may be due to methodological differences or the developmental stage at which experiments were performed. However, it remains that none of these earlier studies directly examined the role of AKT activity in mGluR-LTD. To address this gap, we targeted AKT directly using multiple approaches, including pharmacological agents and genetic removal of *Akt*.

Our results strongly support the idea that AKT normally acts to inhibit mGluR-LTD. We found that blockade of AKT activity with multiple separate approaches, using two different AKT inhibitors, genetic deletion of both *Akt1* and *Akt3* in CA1 as well as PI3K inhibition, all resulted in enhanced mGluR-LTD ([Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}). By using two AKT inhibitors that have different mechanisms of action on AKT, complemented by genetically removing AKT, we addressed potential off-target effects of the compounds and provide converging evidence that the enhanced mGluR-LTD is due to specific inhibition of AKT. Developmental effects of AKT removal also are unlikely to contribute to the observed LTD enhancement as single *Akt* isoform deletion did not affect mGluR-LTD ([Figure 7](#fig7){ref-type="fig"}). Additionally, in the double *Akt1/Akt3* deletion experiment, AKT1 is removed postnatally, eliminating potential confounds from the loss of multiple AKT isoforms during development. Combined, these data show that the role of AKT in mGluR-LTD may be more complex than originally thought. AKT may not simply be a facilitator of general mTORC1-mediated translation but may only be involved in regulating distinct pools of mGluR-induced protein synthesis, some of which may act to inhibit mGluR-LTD. In agreement with this idea, the AKT-TSC pathway has been suggested to act as a brake on mTOR-regulated protein synthesis, while the ERK pathway, which is also activated by mGluR stimulation, promotes protein synthesis ([@bib3]). Indeed, at 60 min post-DHPG, we found increased phosphorylation levels of ERK and S6 in cA1F/A3K mice compared with vehicle treatment but not in WT mice. This suggests that AKT1 and AKT3 removal may relieve the brake on protein synthesis after mGluR stimulation, leading to altered protein synthesis or AMPA receptor internalization and subsequently enhanced mGluR-LTD. Future studies examining these possibilities will be important to resolve the role of AKT in regulating these important pathways in mGluR-LTD.

In summary, this study provides valuable new insights into the role of AKT and its isoforms in the brain. The results show expression differences between AKT isoforms in the hippocampus, affecting their role in synaptic plasticity and protein synthesis. Hence, compounds targeting single AKT isoforms may be an attractive therapeutic target for treating disorders and diseases that impact synaptic plasticity.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                                 Designation                                                 Source or reference             Identifiers                                                                   Additional information
  or resource                                                                                                                                                                                                                       
  ------------------------------------------------------- ----------------------------------------------------------- ------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------
  Antibody                                                Rabbit anti-AKT1 (Western blot)                             Cell Signaling                  Cat\# 2938;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_915788](https://scicrunch.org/resolver/AB_915788)                    

  Antibody                                                Rabbit anti-AKT1 (Immunostaining)                           Cell Signaling                  Cat\# 75692;\                                                                 1:100
                                                                                                                                                      RRID:[AB_2716309](https://scicrunch.org/resolver/AB_2716309)                  

  Antibody                                                Rabbit anti-AKT1 phospho serine 473                         Cell Signaling                  Cat\# 9081;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_11178946](https://scicrunch.org/resolver/AB_11178946)                

  Antibody                                                Mouse anti-AKT2 (Western blot)                              LSBio                           Cat\# LS-C156232;\                                                            1:1000
                                                                                                                                                      RRID:[AB_2716310](https://scicrunch.org/resolver/AB_2716310)                  

  Antibody                                                Rabbit anti-AKT2 (Immunostaining)                           Cell Signaling                  Cat\# 2964;\                                                                  1:100
                                                                                                                                                      RRID:[AB_331162](https://scicrunch.org/resolver/AB_331162)                    

  Antibody                                                Rabbit anti-AKT2 phospho serine 474                         Cell Signaling                  Cat\# 8599;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_2630347](https://scicrunch.org/resolver/AB_2630347)                  

  Antibody                                                Rabbit anti-AKT3 (Western blot)                             Cell Signaling                  Cat\# 14293;\                                                                 1:1000
                                                                                                                                                      RRID:[AB_2629491](https://scicrunch.org/resolver/AB_2629491)                  

  Antibody                                                Mouse anti-AKT3 (Western blot)                              Cell Signaling                  Cat\# 8018;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_10859371](https://scicrunch.org/resolver/AB_10859371)                

  Antibody                                                Rabbit anti-AKT3 (Immunostaining and immunoprecipitation)   Cell Signaling                  Cat\# 14982;\                                                                 1:100 Immunostaining1:50 immunoprecipitation
                                                                                                                                                      RRID:[AB_2716311](https://scicrunch.org/resolver/AB_2716311)                  

  Antibody                                                Rabbit anti-AKT phospho serine 473                          Cell Signaling                  Cat\# 3787;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_331170](https://scicrunch.org/resolver/AB_331170)                    

  Antibody                                                Rabbit anti-AKT                                             Cell Signaling                  Cat\# 4685;\                                                                  1:2000
                                                                                                                                                      RRID:[AB_2225340](https://scicrunch.org/resolver/AB_2225340)                  

  Antibody                                                Rabbit anti-TSC2 S939 phospho serine 939                    Cell Signaling                  Cat\# 3615;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_2207796](https://scicrunch.org/resolver/AB_2207796)                  

  Antibody                                                Rabbit anti-TSC2                                            Cell Signaling                  Cat\# 3635;\                                                                  1:1000
                                                                                                                                                      RRID:[AB_10692893](https://scicrunch.org/resolver/AB_10692893)                

  Antibody                                                Rabbit anti-PDK1 phospho serine 241                         Cell Signaling                  Cat\# 3061;\                                                                  1:3000
                                                                                                                                                      RRID:[AB_2161919](https://scicrunch.org/resolver/AB_2161919)                  

  Antibody                                                Rabbit anti-PDK1                                            Cell Signaling                  Cat\# 3062;\                                                                  1:2000
                                                                                                                                                      RRID:[AB_2236832](https://scicrunch.org/resolver/AB_2236832)                  

  Antibody                                                Rabbit anti-GAPDH                                           Cell Signaling                  Cat\# 2118;\                                                                  1:10000
                                                                                                                                                      RRID:[AB_561053](https://scicrunch.org/resolver/AB_561053)                    

  Antibody                                                Mouse anti-β actin                                          Abcam                           Cat\# 8226;\                                                                  1:10000
                                                                                                                                                      RRID:[AB_306371](https://scicrunch.org/resolver/AB_306371)                    

  Antibody                                                Mouse anti-NeuN                                             Novus                           Cat\# NBP1-92693;\                                                            1:1000
                                                                                                                                                      RRID:[AB_11036146](https://scicrunch.org/resolver/AB_11036146).               

  Antibody                                                Chicken anti-GFAP                                           PhosphoSolutions                Cat\# 621-GFAP;\                                                              1:1000
                                                                                                                                                      RRID:[AB_2492125](https://scicrunch.org/resolver/AB_2492125)                  

  Antibody                                                Rabbit anti-GSK-3β phospho serine 9                         Cell Signaling                  Cat\# 9323;\                                                                  1:3000
                                                                                                                                                      RRID:[AB_2115201](https://scicrunch.org/resolver/AB_2115201)                  

  Antibody                                                Rabbit anti- GSK-3β                                         Cell Signaling                  Cat\# 9315;\                                                                  1:3000
                                                                                                                                                      RRID:[AB_490890](https://scicrunch.org/resolver/AB_490890)                    

  Antibody                                                Mouse anti-GluA2                                            NeuroMAB                        Clone N355/1;\                                                                1:1000
                                                                                                                                                      RRID:[AB_2315839](https://scicrunch.org/resolver/AB_2315839)                  

  Antibody                                                Rabbit anti-S6 phospho S235/236                             Cell Signaling                  Cat\# 4856;\                                                                  1:2000
                                                                                                                                                      RRID:[AB_2181037](https://scicrunch.org/resolver/AB_2181037)                  

  Antibody                                                Rabbit anti-S6                                              Cell Signaling                  Cat\# 2217;\                                                                  1:2000
                                                                                                                                                      RRID:[AB_331355](https://scicrunch.org/resolver/AB_331355)                    

  Antibody                                                Mouse anti-puromycin                                        Abcam                           12D10;\                                                                       1:1000
                                                                                                                                                      RRID:[AB_2566826](https://scicrunch.org/resolver/AB_2566826)                  

  Antibody                                                Rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)    Cell Signaling                  Cat\# 9101;\                                                                  1:4000
                                                                                                                                                      RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646)                    

  Antibody                                                Rabbit p44/42 MAPK (Erk1/2) Antibody                        Cell Signaling                  Cat\#9102; 9102S RRID:[AB_330744](https://scicrunch.org/resolver/AB_330744)   1:4000

  Antibody                                                Donkey anti-Rabbit-Cy3                                      Jackson ImmunoResearch          Cat\# 711-165-152;\                                                           1:200
                                                                                                                                                      RRID:[AB_2307443](https://scicrunch.org/resolver/AB_2307443)                  

  Antibody                                                Donkey anti-Mouse Alexa 488                                 Jackson ImmunoResearch          Cat\# 715-545-150;\                                                           1:200
                                                                                                                                                      RRID:[AB_2340846](https://scicrunch.org/resolver/AB_2340846)                  

  Antibody                                                Donkey anti-Chicken Alexa 647                               Jackson ImmunoResearch          Cat\# 703-605-155;\                                                           1:200
                                                                                                                                                      RRID:[AB_2340379](https://scicrunch.org/resolver/AB_2340379)                  

  Chemical compound, drug                                 Hoechst                                                     Sigma                           Cat\# H6024                                                                   1:3000

  Antibody                                                Goat anti-mouse HRP                                         Promega                         W4020                                                                         1:5000

  Antibody                                                Goat anti-rabbit HRP                                        Promega                         W4011                                                                         1:5000

  Chemical compound, drug                                 MK-2206-2HCl                                                Selleckchem                     Cat \# S1078                                                                  

  Chemical compound, drug                                 AZD5363                                                     Selleckchem                     Cat \# S1078                                                                  

  Chemical compound, drug                                 LY294002                                                    Sigma                           Cat \# L9908                                                                  

  Other                                                   A/G agarose beads                                           Pierce                          Cat\# 20421                                                                   

  Chemical compound, drug                                 Protease inhibitor                                          Sigma                           P8340                                                                         

  Chemical compound, drug                                 Phosphatase inhibitor II                                    Sigma                           P5726                                                                         

  Chemical compound, drug                                 Phosphatase inhibitor III                                   Sigma                           P0044                                                                         

  Chemical compound, drug                                 Puromycin                                                   Sigma                           P8833                                                                         

  Chemical compound, drug                                 (RS)−3,5- DHPG                                              Tocris                          Cat\# 0342                                                                    

  Commercial assay or kit                                 ECL Prime Western blot Detection                            GE Healthcare                   RPN2236                                                                       

  *Mus Musculus*, *Akt1^tm1Mbb^*, C57BL/6 ()              *Akt1* KO                                                   Jackson Laboratory              Stock \# 004912;\                                                             
                                                                                                                                                      RRID:[IMSR_JAX:004912](https://scicrunch.org/resolver/IMSR_JAX:004912)        

  *Mus Musculus*, *Akt2^tm1.1Mbb^*, C57BL/6 ()            *Akt2* KO                                                   Jackson Laboratory              Stock \# 006966;\                                                             
                                                                                                                                                      RRID:[IMSR_JAX:006966](https://scicrunch.org/resolver/IMSR_JAX:006966)        

  *Mus Musculus*, *Akt3^tm1.3Mbb^*, C57BL/6 ()            *Akt3* KO                                                   [@bib9]; PMCID: PMC549378                                                                                     Obtained from Birnbaum lab (UPenn) in 2012

  *Mus musculus*, *Akt1^tm2.2Mbb^*, C57BL/6 ()            *Akt1^loxP/loxP^*                                           Jackson Laboratory              Stock \#026474;\                                                              
                                                                                                                                                      RRID:[IMSR_JAX:026474](https://scicrunch.org/resolver/IMSR_JAX:026474)        

  *Mus Musculus*, *Akt2^tm1.2Mbb^*, C57BL/6 ()            *Akt2^loxP/loxP^*                                           Jackson Laboratory              Stock \#026475;\                                                              
                                                                                                                                                      RRID:[IMSR_JAX:026475](https://scicrunch.org/resolver/IMSR_JAX:026475)        

  *Mus Musculus*, *Tg^(CamkIIa-Cre)T29Stl^*, C57BL/6 ()   *CamK2a*-Cre                                                [@bib20]; PMCID: PMC2630531                                                                                   Obtained from Kelleher lab (MIT) in 2008

  *Mus Musculus*, *Tg^(Eno2-cre)39Jme^*, C57BL/6 ()       *Eno2*-Cre -or-\                                            Jackson Laboratory              Stock \# 005938;\                                                             
                                                          *NSE39*-Cre                                                                                 RRID:[IMSR_JAX:005938](https://scicrunch.org/resolver/IMSR_JAX:005938)        

  *Mus Musculus*, *Tg^(Nes-cre)1Kln^*, C57BL/6 ()         *Nestin*-Cre                                                Jackson Laboratory              Stock \# 003771;\                                                             
                                                                                                                                                      RRID:[IMSR_JAX:003771](https://scicrunch.org/resolver/IMSR_JAX:003771)        

  Software, algorithm                                     IBM SPSS Statistics                                         IBM Analytics                   RRID:[SCR_002865](https://scicrunch.org/resolver/SCR_002865)                  

  Software, algorithm                                     pCLAMP software                                             Molecular Devices               RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)                  

  Software, algorithm                                     ImageQuant TL                                               GE Healthcare                   RRID:[SCR_014246](https://scicrunch.org/resolver/SCR_014246)                  

  Software, algorithm                                     ICY Imaging                                                 Other                           RRID:[SCR_010587](https://scicrunch.org/resolver/SCR_010587)                  Open Source; <http://icy.bioimageanalysis.org/>

  Other                                                   Cryostat                                                    Leica CM1850                                                                                                  

  Other                                                   Nikon A1R Laser Scanning Confocal                           Nikon                                                                                                         

  Other                                                   Vibratome                                                   Leica VT1200S                                                                                                 

  Other                                                   Brain slice incubation chamber                              Scientific Systems Design Inc   BSC1                                                                          

  Other                                                   Proportional Temperature Controller                         Scientific Systems Design Inc   PTC03                                                                         

  Other                                                   Microelectrode AC Amplifier Model 1800                      A-M Systems                     Cat \# 70000                                                                  

  Other                                                   Axon CNS Digidata 1440A                                     Molecular Devices                                                                                             

  Other                                                   Sonicator XL2000                                            QSonica                                                                                                       

  Other                                                   Synergy 2 Multimode reader                                  BioTek                                                                                                        

  Other                                                   XCell II Surelock Western blot                              ThermoFisher Scientific         EI0002                                                                        

  Other                                                   Novex 4--12% Bis-Tris gels (15 or 26 well)                  Life Technologies               15 well: NP0336                                                               

  26 well: WG1403                                                                                                                                                                                                                   

  Other                                                   FluorChem E system                                          Proteinsimple                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Akt1* KO ([@bib8]), *Akt2* KO ([@bib7]) and *Akt3* KO ([@bib9]) male mice were generated in the C57/BL6 background. To generate mice that have conditional *Akt1* or *Akt2* removal in excitatory neurons in the forebrain, we bred *Akt1*^loxP/loxP^([@bib50]) or *Akt2*^loxP/loxP^ ([@bib32]) with *Camk2a*-Cre (T-29--1) ([@bib51]), rat neuron-specific enolase, NSE or *Eno2-*Cre (NSE39-Cre, Jax Labs) or *Nestin*-Cre (Jax Labs) mice, all in the C57/BL6 background. Age-matched wild-type (WT) male littermates were used as controls for this study. Mice were housed at 21°C, maintained on a 12 hr light/dark schedule with food and water available *ad libitum* and tested at 5--20 weeks of age, depending on the experimental protocol. All procedures were approved by the University of Colorado, Boulder Animal Care and Use Committee.

Immunohistology {#s4-2}
---------------

WT and *Akt* mutant mice were anesthetized using a mixture of pentobarbital sodium and phenytoin sodium (Euthanasia III). When they were unresponsive to a toe pinch, mice were intracardially perfused with PBS followed by 4% paraformaldehyde (PFA). After perfusion, brains were isolated and kept in 4% PFA for 24 hr at 4°C. Brains were then transferred to 30% sucrose in PBS for at least 24 hr at 4°C. Next, brains were sectioned into 30 µm coronal slices on a cryostat (Leica) and stored at −20°C in cryoprotectant (20% glycerol/2% DMSO in phosphate buffer) until used for immunohistology. Fluorescent immunostaining was performed as described previously with minor changes ([@bib34]). Briefly, free-floating brain sections were washed with PBS and submitted to heat-mediated antigen retrieval in citrate buffer (10 mM, pH 6) if needed. Slices were blocked for 1 hr at room temperature in staining buffer containing 0.05 M Tris pH 7.4, 0.9% NaCl, 0.25% gelatin, 0.5% TritonX-100, and 2% donkey serum. Slices were then incubated overnight at 4°C with primary antibodies against AKT1 (1:100, Cell Signaling D9R8K, central amino acid of epitope is D108), AKT2 (1:100, Cell Signaling 5B5, central amino acid of epitope is P471), AKT3 (1:100, Cell Signaling E1Z3W, central amino acid of epitope is E131), NeuN (1:1000, Millipore Mab377), and GFAP (1:1000, PhosphoSolutions 621-GFAP) diluted in staining buffer with 2% donkey serum. After three washes in PBS, the brain slices were incubated at room temperature for 2 hr in Cy3-conjugated anti-rabbit, 488-conjugated anti-mouse and Cy5-conjugated anti-chicken secondary antibodies (1:200, Jackson Immunoresearch) diluted in staining buffer with Hoechst dye (1:3000). Following three washes in PBS, slices were mounted and coverslipped with Mowiol. Brain slices were imaged using the Nikon A1R confocal microscope. Z-stacks through the entire thickness of the slice were taken at 20x and 100x. All microscope parameters were held constant across all slices.

Field electrophysiology {#s4-3}
-----------------------

Long-term potentiation (LTP) and long-term depression (LTD) in the CA3-CA1 circuit from acute 400 µm transverse hippocampal slices were recorded as previously described ([@bib51]; [@bib34]). Hippocampal slices were derived from mice 5--6 weeks of age for LTD experiments and greater than 10 weeks of age for LTP experiments. Briefly, slices were maintained in an interface chamber at 32°C infused with oxygenated ACSF containing (in mM): 125 NaCl, 2.5 KCl, 1.25 aH~2~PO~4~, 25 NaHCO~3~, 25 D-glucose, 2 CaCl~2~ and 1 MgCl~2~. For LFS-LTD recordings, slices were maintained in ACSF containing 2.5 mM CaCl~2~. Slices recovered in the chamber at least 60 min prior to recordings. Next, constant-current stimuli (100 μs) were delivered with a bipolar silver electrode placed in the stratum radiatum of area CA3, and field excitatory postsynaptic potentials (fEPSPs) were recorded with an electrode filled with ACSF in the stratum radiatum of area CA1. fEPSPs were monitored by delivering stimuli at 0.033 Hz and measuring their slopes using pCLAMP10 (Molecular Devices). Before LTP or LTD induction, a stable baseline was established for 20--30 min with a stimulus intensity of 40--50% of the maximum fEPSP. Late-phase LTP (L-LTP) was induced by four trains of 100 Hz high-frequency stimulation (HFS) for 1 s with a 5-min intertrain interval. LFS-LTD was induced by 900 stimuli of 1 Hz. For drug treatments, 100 µM (RS)−3,5-DHPG (Tocris Bioscience, Minneapolis, MN), 30 µM MK-2206 2HCL (Selleckchem, Houston, TX), 30 µM AZD5363 (Selleckchem), 50 µM LY294002 (Sigma, St. Louis, MO), or vehicle was applied to the ACSF.

Puromcyin-labeled protein synthesis assay {#s4-4}
-----------------------------------------

Newly synthesized proteins were labeled using an adaption of the SUnSET protocol as described in ([@bib19]). To control for metabolic state differences between mice, only slices generated from a single mouse are used for all testing conditions. Briefly, hippocampal slices were prepared for field electrophysiology as described earlier. Immediately after HFS was delivered to induce L-LTP, hippocampal slices were incubated with puromycin (10 µg/ml) in ACSF for 30 min at 32°C. After puromycin labeling, slices were flash frozen on dry ice and processed for Western blot analysis.

Drug concentration assay {#s4-5}
------------------------

Hippocampal slices were prepared as described above but were maintained at room temperature for 1 hr in oxygenated ACSF prior to being transferred to vials containing oxygenated ACSF at 32°C for 1 hr. Then, slices were treated with AKT inhibitors for 30 min and flash frozen on dry ice to be processed for Western blot analysis.

Immunoprecipitation {#s4-6}
-------------------

Because a specific phospho-AKT3 antibody was not available to measure phosphorylation levels of AKT3, AKT3 protein was purified from AKT inhibitor-treated slices and from *Akt1* KO and WT hippocampal tissue. These tissues were homogenized by sonication in ice-cold immunoprecipitation (IP) buffer containing in mM: 40 HEPES pH 7.5, 150 NaCl, 10 pyrophosphate, 10 glycerophosphate, 1 orthovanadate, 1 EDTA, 1 EGTA, and 50 NaF; 1X protease inhibitor cocktail III and phosphatase inhibitor cocktails II and III (Sigma); and 0.1% Triton X-100. 100 µg of the lysates were diluted to 100 µL in IP buffer and incubated with anti-AKT3 antibody (Cell Signaling, Beverly, MA, E1Z3W) at 100:1 v/v, shaking gently overnight at 4°C. Samples were then incubated with 50 µL of slurry containing IgG-bound agarose beads (Pierce, Waltham, MA), shaking gently overnight at 4°C, followed by centrifugation at 2500 *g* for 4 min at 4°C. The bead pellet containing immunoprecipitated AKT3 protein was washed twice with IP buffer and resuspended with Laemmli buffer to twice the pellet volume. 20 µL of the samples were then used for western blotting to examine phospho-AKT3 levels with the phospho-AKT S473 antibody.

Western blot analysis {#s4-7}
---------------------

Either freshly extracted tissue or treated hippocampal slices were flash frozen on dry ice. Soluble protein extracts were prepared for western blotting using procedures adapted from previous studies ([@bib51]). Briefly, WT, mutant or drug-treated hippocampal slices or tissue were homogenized by sonication in lysis buffer containing (in mM): 10 HEPES pH 7.4, 150 NaCl, 50 NaF, 1 EDTA, 1 EGTA, and 10 Na~4~P~2~O~7~ with 1x protease inhibitor cocktail III (Sigma), 1x phosphatase inhibitor cocktails II and III (Sigma), 1% Triton-X, and 1% Igepal. 20- or 30 µg protein samples were prepared in Laemmli sample buffer and resolved using 4--12% Bis-Tris gradient gels. Proteins were then blotted on PDVF membrane and detected using standard techniques. Protein blots were blocked with 0.2% I-Block (Tropix-Thermo Fisher, Lafayette, CO) dissolved in Tris-buffered saline with 0.1% Tween-20 (TBS-T). Primary antibodies were diluted in I-Block and incubated for 24 hr at 4°C. Blots were washed in TBS-T followed by incubation with HRP-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (1:5000, Promega, Madison, WI) to detect the primary antibody. Immunoreactive signals were visualized with enhanced chemiluminescence (GE Healthcare) and quantified in the linear range of detection as previously described ([@bib51]). Signals were normalized by total protein levels for phospho-proteins or by loading control levels for total proteins. Primary antibodies used were puromycin (mouse monoclonal 12D10), AKT1 (1:1000, Cell Signaling C73H10), phospho-AKT1 S473 (1:1000, Cell Signaling D7F10), AKT2 (1:1000, LSBio, Seattle, WA, LS-C156232), phospho-AKT2 474 (1:1000, Cell Signaling D3H2), AKT3 (1:1000, Cell Signaling E2B6R), AKT3 (1:1000, Cell Signaling L47B1), phospho-AKT S473 (1:1000, Cell Signaling 736E11), pan-AKT (1:2000, Cell Signaling 11E7), phospho-GSK-3β S9 (1:3000, Cell Signaling 5B3), GSK-3β (1:3000, Cell Signaling 27C10), phospho-TSC2 S939 (1:1000, Cell signaling 3615), TSC2 (1:1000, Cell Signaling 3635), phospho-PDK1 S241 (1:3000, Cell Signaling 3061), PDK1 (1:2000, Cell Signaling 3062), phospho-S6 235/236 (1:2000, Cell Signaling 4856), S6 (1:2000, Cell Signaling 2217), phospho-ERK1/2 (1:4000, Cell Signaling 9101), ERK1/2 (1:4000, Cell Signaling 9102), Mouse anti-GluA2 (1:1000, NeuroMAB, Davis, CA), β-actin (1:10000, Abcam, Cambridge, MA), and GAPDH (1:10000, Cell Signaling 14C10).

Statistical analysis {#s4-8}
--------------------

All data are presented as mean values ± SEM. Data were statistically evaluated using SPSS software. The use of parametric tests was determined with the Shapiro-Wilk test for normality and Student's *t* test or ANOVA were applied. Outliers were excluded using Grubb's method. Repeated measures (RM) ANOVA were used for electrophysiological experiments with time as the within-subjects factor. Significant effects were followed by Tukey's post hoc testing. All statistical tests were two-tailed with p\<0.05 considered as statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"AKT isoforms have distinct hippocampal expression and roles in synaptic plasticity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Kimberly M Huber (Reviewer \#1); Clive Bramham (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. There were differing opinions about the suitability of the paper for the journal.

In this paper, the distribution and function of the AKT family of genes in hippocampus synaptic plasticity was studied. The authors find roles for AKT1 in L-LTP and redundant roles for AKT1 and AKT3 in the suppression of mGluR-LTD. The reviewers indicated the results to be original and show that AKT proteins may play distinct roles in the regulation of protein synthesis during LTD and LTP. However, several reservations were raised about the data to support this conclusion. Specifically, there were concerns raised regarding inconsistencies of the pharmacological findings and the results from AKT knockout mice. The collective concerns are delineated below.

Reviewer \#1:

1\) I commend the authors for doing a thorough job characterizing the AKT inhibitors in the slice preparation in [Figure 3](#fig3){ref-type="fig"}. However, there are some confusing results that may require more explanation. The MK inhibitor at 10um completely blocks P-AKT, but has no effect on its substrate GSK3B, whereas the AZD drug enhanced P-AKT, but inhibits GSK3B phosphorylation. Is AKT autophosphorylated? Or are the distinct effects of the inhibitors due to feedback onto PDK1? It would be good to see the same data in the AKT1 and AKT3 KO mice to see if similar or different effects are observed.

2\) In [Figure 4, a](#fig4){ref-type="fig"} pharmacological and genetic approach is used to study the effect of AKT on L-LTP. The Akt1 isoform is claimed to be the one involved in the maintenance of L-LTP and the target of the pharmacological blockers. Is somehow surprising that in AKT1 KO, the L-LTP seems to be only partially inhibited, whereas both of the pharmacological agents completely block this form of synaptic plasticity. Is the effect of the blockers specific? What is the effect of these inhibitors on the LTP induced in the AKT1 knockout mice.

3\) In [Figure 5](#fig5){ref-type="fig"}, the authors show impaired protein synthesis in AKT1 KO after L-LTP induction. Are there any differences in protein synthesis rate under basal condition in each of the KO mice? That is not reported and would help to interpret the results.

4\) In [Figure 5E--F](#fig5){ref-type="fig"}, the effect of HFS on S6 phosphorylation in AKT1 and AKT3 ko is reported. The phosphorylation of S6 after HFS does not look different in the wild type slice, perhaps because they are saturated. What seems to be different is only the total amount of S6 that is reduced in the WT after HFS. It would be nice to see a loading control, actin or tubulin?, for these western. Also in this case, knowing the effect of AKT1 and AKT3 absence on basal level of S6 phosphorylation would help to interpret the results.

5\) The most surprising, and therefore interesting, result in the paper, in my opinion, is [Figure 7](#fig7){ref-type="fig"}, where the authors show enhanced mGlu-LTD using the inhibitors of Akt, and this result is confirmed with PI3K inhibitors and in AKT1/AKT3 CA1 dKO. The authors discuss a role for AKT as a brake on mGlu-LTD and protein synthesis machinery induction. However, they present no data to support this conclusion. Because these authors used SunSET to examine effects of AKT deletion on HFS-induced protein synthesis, this should also be done with mGluR-LTD. This result may suggest that AKT plays distinct roles in protein synthesis regulation depending on the stimulus (LTP or LTD), which in my opinion is very novel and impactful. Also, examining the effects of the inhibitors and AKT deletion on DHPG-induced signaling to mTORC1 and other pathways would provide more mechanistic insight into how AKT does this. However, this could be beyond the scope of this present manuscript.

Reviewer \#2:

The analysis of the mutant mice show that none of them affected synaptic plasticity up to an hour after any stimulation except the double mutant Akt1/3 in [Figure 8](#fig8){ref-type="fig"} (mGluR-DHPG). Only L-LTP at 3 hours showed a decremental effect (incomplete LTP block) for Akt1 knockouts. They also find impaired protein synthesis in Akt1 knockouts and conclude that the effect on L-LTP is \"through regulating protein synthesis\". They have not shown a causal link, merely a correlation. These findings are a minimal advance, do not present any conceptual advances and are not of the highest technical standards.

The results with the drugs are problematic for the reasons mentioned. The result of enhanced mGluR-LTD with LY294002 is preliminary.

My conclusion is that this not a high interest paper worthy of publication in *eLife*.

Specific points in the order they arise in the manuscript:

1\) The introduction to the Akt family is confusing and non-standard with respect to genes, gene families and proteins. The authors refer to \"three highly related isoforms\". There are many splice isoforms described for each of three genes (see Ensemble and UniProt). Nowhere to they explain that they are referring to three genes, and each one expresses multiple splice isoforms. A figure with relevant schematic sequence alignments of the proteins and explanation of the isoforms and paralogs would be useful, showing where the antibodies bind and where the location of domains that bind to the drugs. This would enable the reader to understand the limitations of the specificity of the reagents.

2\) The differential expression of the three genes shown using immunolabelling in [Figure 1](#fig1){ref-type="fig"} appears to describe differential expression, with Akt2 showing most differences to Akt1 and 3. An inspection of expression data in the Allen References Atlas shows Akt1,2 and 3 are expressed in all principal neurons, but Ak2 is at lower levels than either Akt1 and 3. Inspection of single-cell transcriptome data (Zeisel et al.,1934) shows that all three genes are expressed in many cell types in the hippocampus. The authors argue that the Cre lines (Supplementary [Figure 1](#fig1){ref-type="fig"}) show evidence that Akt2 is not expressed, however these blots are overexposed (and not quantified) and the lack of reduction in Cre lines will have limited sensitivity (I doubt if it would detect a 20% reduction). Thus, I would suggest the authors caution their statements \"that Akt2 is not expressed in hippocampal neurons\" (and cite these other sources of expression data) and that \"Akt2 is specifically expressed in astrocytes\". The authors could describe them as enriched in the particular cells.

3\) Characterization of Akt inhibitors. Here the authors incubate brain slices with two different inhibitors and measure \"the phosphorylation of Akt\". Surely, it's important to measure the phosphorylation of each individual Akt isoform? This could be achieved by immunoprecipitation of each form followed by phosphoAKT blotting. Have these inhibitors been tested on Akt1, 2 and 3?

4\) The authors say that AZD inhibitor increases pAKT S473, however the blot in [Figure 3A](#fig3){ref-type="fig"} is not convincing (the 30 and 100micM bands look the same as vehicle).

5\) The dissociation between the dose-dependent effects of MK and AZD on pAKTS473 and pGSK3bS9 is confusing. Why do both drugs inhibit pGSK3bS9 when MK blocks pAKTS473 and AZD increases pAKTS473? The authors refer to a paper (Okuzumi, et al., 2009) that describes an interesting phenomenon of \"inhibitor hijacking\" that may be relevant. The original paper does not describe this effect on the different Akt proteins and the experiments suggested in point 3 would also address this.

6\) They decide to use the inhibitors at 30micM. This is a very high dose, especially when the MK drug strongly inhibits pAKTS473 at 10micM. ATP-competitive inhibitors are notorious for the poor specificity between families of kinases and it is typical to test the potential for non-specific inhibition of kinases. Using similar phospho-blots as in [Figure 3](#fig3){ref-type="fig"}, the authors could confirm that the doses they use are not interfering with other kinases that are known to interfere with LTP.

7\) [Figure 4.](#fig4){ref-type="fig"} L-LTP inhibition. [Figure 4A and B](#fig4){ref-type="fig"} show the effects of the two inhibitors and from about 50\' the drug-treated slices show a decremental LTP. In Supplementary [Figure 2](#fig2){ref-type="fig"}, the effect of the inhibitors on the baseline is only recorded for 30\'. An important control that is missing is to record baseline for the same duration as the L-LTP experiments (200+ minutes). In the absence of this it is not possible to claim that \"activity of AKT is required to sustain long-lasting LTP\".

8\) L-LTP experiment are technically very demanding and it is very easy to obtain decremental L-LTP simply as a result of poor health of the slice. To control for this, it is standard practice to perform 2-pathway experiments.

9\) Since AKT inhibitors reduced L-LTP and pGSK3bS9, then it might be expected that Akt1-knockouts would also show reduced pGSK3bS9. But in [Figure 6A](#fig6){ref-type="fig"}, apparently, this is not the case. Another dissociation is the reduction in pGSK3bS9 seen in Akt3 KO mice, which show normal L-LTP. This is confusing and important (the doses of the drugs were chosen on the basis that they inhibit pGSK3bS9).

10\) [Figure 5](#fig5){ref-type="fig"}. Are statistics for slices or mice?

11\) [Figure 7](#fig7){ref-type="fig"}, mGluR-LTD, would also benefit from 2-pathway experiments (they also exceed the 30 min baseline in the control Supplementary [Figure 2](#fig2){ref-type="fig"}.

12\) The discrepancy between the results of LY294002 on mGluR-LTD is concerning. The original paper (Hou and Klann, 2004) showed they could reproduce the result with wortmannin. They also used an inactive structural analogue (LY294002), which had no effect. Given the controversial nature of this result, the authors should try these two other controls.

13\) [Figure 8](#fig8){ref-type="fig"}, double mutant mice. This is a very nice line of investigation, especially since there is overlap of expression in Akt1 and Akt3. I am very surprised the authors have not performed the L-LTP experiment (and protein synthesis, and phosoph blots) to see if the partial effect on L-LTP in Akt1 kos is not further reduced in the double mutants.

Reviewer \#3:

The is a solid paper with important new findings on Akt-isoform specific localization, signaling, and function in the hippocampus. The authors have effectively combined knockouts and conditional gene deletion strategies with pharmacology. The results are clear and the story is compelling and novel. Akt1, but not Akt3, supports activity-induced protein synthesis in L-LTP. Akt1 works in concert with Akt3 to inhibit mGluR-LTD, which is a completely unanticipated but well-documented finding. The article is well-written and the controversial findings, implications, and future directions are all discussed. I have only minor comments (below).

1\) From the staining shown in [Figure 1](#fig1){ref-type="fig"}, it looks like Akt1 and Akt3 are expressed in the neuropil (synaptic/dendritic). The enzymes are not exclusively somatic. The authors should comment on this.

The synaptic/dendritic localization of Akt1 and Akt3 is an extremely important issue in view of the role of dendritic protein synthesis in synaptic maintenance and plasticity. PI3K/Akt signaling to mTOR has been shown to increase dendritic translation in CA1 by many labs. The authors mention the need for studies on localization but should spell out the need for work on Akt isoform signaling in local protein synthesis.

2\) [Figure 1](#fig1){ref-type="fig"}. There appears to be a gap in Akt3 staining in the CA1 region. Is this representative or an artefact? This segment does not seem to correspond to CA2, but there is a lot of interest in CA2 recently. The authors could comment on the distribution of Akt in CA2.

3\) The electrophysiology is from CA1. The authors should state in subsection "Akt1 deletion results in impaired protein synthesis after L-LTP induction"and the first paragraph of the Discussion section (and elsewhere, if applicable) that the findings on L-LTP/mGluR-LTD are from CA1.

4\) Akt1 and Akt3 are shown to have different roles in protein synthesis, and there appears to be a differential distribution of the enzymes in CA1, CA3, and DG. It is notable in this context that rapamcyin blocks L-LTP and CA1 but does not affect L-LTP in the DG (Panja et al., 2009, 2014). The regional differences in L-LTP and translation might be related to differential activation of Akt isoforms.

With regard to the 2 pathway experiments raised by Reviewer \#2, we feel that this could be addressable if the AKT inhibitors do not cause baseline synaptic transmission to run down over the course of the 1-2 hour duration of the L-LTP experiments. Currently, the effect of the inhibitors is only during a 30 min application.

10.7554/eLife.30640.021

Author response

> Reviewer \#1:
>
> 1\) I commend the authors for doing a thorough job characterizing the AKT inhibitors in the slice preparation in [Figure 3](#fig3){ref-type="fig"}. However, there are some confusing results that may require more explanation. The MK inhibitor at 10um completely blocks P-AKT, but has no effect on its substrate GSK3B, whereas the AZD drug enhanced P-AKT, but inhibits GSK3B phosphorylation. Is AKT autophosphorylated? Or are the distinct effects of the inhibitors due to feedback onto PDK1? It would be good to see the same data in the AKT1 and AKT3 KO mice to see if similar or different effects are observed.

Originally, we were also surprised by the AZD result but then found that several studies have investigated this phenomenon. This inhibitor-induced "paradoxical" AKT hyperphosphorylation is not due to enhancement of upstream signals to compensate for the AKT signal loss but rather is related to the occupation and binding of this type of inhibitor at the ATP-pocket of AKT. Therefore, the hyperphosphorylation of AKT following AZD is not due to a feedback loop but due to 'intrinsic' mechanisms. Previously, it was shown that binding of the ATP-competitive inhibitor results in translocation of AKT to the membrane (Okuzumi et al., 2009). Here at the membrane it seems that AKT is either more susceptible to phosphorylation (Okuzumi et al., 2009) or more resistant to dephosphorylation (Chan et al., 2011), but either way AKT activity is inhibited. We have now explained this in more detail in the paper. Nevertheless, to make sure there was no feedback loop in brain slices, we tested phosphorylation of PDK1 and found no effect of AZD or MK ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The inhibitory effects of AZD and MK on AKT activity have been tested and verified previously, showing differences in potency, consistent with our dose-dependent GSK3β results (MK2206: AKT~1/2~/3 with IC50 8/12/65 nM^1^; AZD5363: AKT~1/2~/3 with IC50 3/8/8 nM^2^. We also tested the effect of both inhibitors on another AKT substrate, TSC2 and found that this substrate was inhibited as well. Finally, we tested the effect of the inhibitors on each isoform and found that MK2206 dephosphorylates all isoforms and AZD hyperphosphorylates all isoforms. Based on these results, we believe it is unlikely that the drugs will perform differently in the context of an Akt mutant. Additionally, because we did not report any results combining pharmacology with Akt deficient mice, we believe testing the AKT inhibitors in Akt mutants will not provide any significant new information relative to the data already presented.

> 2\) In [Figure 4](#fig4){ref-type="fig"}, a pharmacological and genetic approach is used to study the effect of AKT on L-LTP. The Akt1 isoform is claimed to be the one involved in the maintenance of L-LTP and the target of the pharmacological blockers. Is somehow surprising that in AKT1 KO, the L-LTP seems to be only partially inhibited, whereas both of the pharmacological agents completely block this form of synaptic plasticity. Is the effect of the blockers specific? What is the effect of these inhibitors on the LTP induced in the AKT1 knockout mice.

We agree that both inhibitors block L-LTP stronger compared to Akt1 KO alone. This could suggest that another isoform has an effect as well, most likely AKT3. The absence of an L-LTP impairment with Akt3 KO suggests that AKT1 can compensate for the loss of AKT3 or that AKT1 is the predominant kinase involved in this form of synaptic plasticity. Indeed, our data support the idea that AKT1, but not AKT3, is specifically involved in protein synthesis induced by high frequency stimulation ([Figure 5](#fig5){ref-type="fig"}). To more thoroughly explore this question, the cA1FA3K double mutants would be the best model to answer this question, and we have planned to examine L-LTP in this model for future studies. However, we believe this is beyond the scope of the current study because it is primarily focused on the role of single isoforms in synaptic plasticity. Another detail, as may be noticed from [Figure 8A](#fig8){ref-type="fig"}, is that the double mutants are rather difficult to generate (1 in 8 mice, or 1 mouse per 2 litters, will be a male double mutant); therefore, we chose instead to use the mice generated in our revision time frame for slices to answer point 5 made by this reviewer.

> 3\) In [Figure 5](#fig5){ref-type="fig"}, the authors show impaired protein synthesis in AKT1 KO after L-LTP induction. Are there any differences in protein synthesis rate under basal condition in each of the KO mice? That is not reported and would help to interpret the results.

We agree this would be very interesting. In the current paper, we controlled for basal protein synthesis differences between animals by performing the puromycin-labeling experiments within each animal, meaning that slices obtained from a singleanimal were either not stimulated or stimulated using HFS. The stimulated slices were then compared to the unstimulated slices for each animal to examine protein synthesis rates. This was repeated for each genotype separately. This approach is necessary because basal labeling rates can vary between different animals. Several factors can account for this, such as recent metabolism stimulation (i.e. feeding), sleep, and other factors that are difficult to control for across individual mice. Therefore, even though this would be a great question to answer, other strategies might be better used to address it. In future studies, we plan to employ a luciferase translation reporter to measure synthesis rates both in culture and in vivo.

> 4\) In [Figure 5E--F](#fig5){ref-type="fig"}, the effect of HFS on S6 phosphorylation in AKT1 and AKT3 ko is reported. The phosphorylation of S6 after HFS does not look different in the wild type slice, perhaps because they are saturated. What seems to be different is only the total amount of S6 that is reduced in the WT after HFS. It would be nice to see a loading control, actin or tubulin?, for these western. Also in this case, knowing the effect of AKT1 and AKT3 absence on basal level of S6 phosphorylation would help to interpret the results.

At the reviewer's suggestion, we have included loading controls (GAPDH) for these westerns. We agree with the reviewer that the enhanced pS6 in WT samples after HFS seems largely due to reduced total S6 levels. We observed a similar phenomenon in an earlier study (3). So, while we agree that a simpler result would have been increased pS6 with no change in total S6 levels, it appears that consistent with previous results pS6 increases are driven by changes in total S6 protein. A previous study has also shown that basal pS6 levels are reduced in *Akt3* KO mice but not affected in *Akt1* KO mice (4). We observed the same results but because this was known and we were interested in how the *Akt* mutants responded to HFS, we had chosen to present our data to focus on their protein synthesis response post-HFS for clarity considerations. However, to address this point, we have now added discussion about pS6 levels basally.

> 5\) The most surprising, and therefore interesting, result in the paper, in my opinion, is [Figure 7](#fig7){ref-type="fig"}, where the authors show enhanced mGlu-LTD using the inhibitors of Akt, and this result is confirmed with PI3K inhibitors and in AKT1/AKT3 CA1 dKO. The authors discuss a role for AKT as a brake on mGlu-LTD and protein synthesis machinery induction. However, they present no data to support this conclusion. Because these authors used SunSET to examine effects of AKT deletion on HFS-induced protein synthesis, this should also be done with mGluR-LTD. This result may suggest that AKT plays distinct roles in protein synthesis regulation depending on the stimulus (LTP or LTD), which in my opinion is very novel and impactful. Also, examining the effects of the inhibitors and AKT deletion on DHPG-induced signaling to mTORC1 and other pathways would provide more mechanistic insight into how AKT does this. However, this could be beyond the scope of this present manuscript.
>
> We agree with the reviewer that this is of great interest and therefore attempted to address this point with new data in [Figure 8](#fig8){ref-type="fig"}. Intriguingly, these results show that TSC2 signaling, upstream of mTORC1, is not altered whereas ERK signaling is enhanced in the double KO mice 60 min after DHPG treatment, leading to increased p-S6 signaling as well. This suggests that protein synthesis is indeed enhanced in cA1FA3K mice and that AKT1 and AKT3 together normally act as a brake on mGluR-LTD and the underlying protein synthesis. Owing to material (slice availability) and time constraints, we did not perform SuNSET analyses with the double mutant cA1F/A3K mice. The SuNSET protocol in our hands requires nearly all the slices generated from a single mouse to provide sufficient materials for control, stimulated and unlabeled experimental samples with technical replicates.
>
> Reviewer \#2:
>
> 1\) The introduction to the Akt family is confusing and non-standard with respect to genes, gene families and proteins. The authors refer to \"three highly related isoforms\". There are many splice isoforms described for each of three genes (see Ensemble and UniProt). Nowhere to they explain that they are referring to three genes, and each one expresses multiple splice isoforms. A figure with relevant schematic sequence alignments of the proteins and explanation of the isoforms and paralogs would be useful, showing where the antibodies bind and where the location of domains that bind to the drugs. This would enable the reader to understand the limitations of the specificity of the reagents.

We apologize that the background on the AKT family was confusing. The manuscript now explains in more detail that we are examining three AKT protein isoforms and each isoform is generated from a different gene (highlighted). While indeed Ensembl describes multiple splice isoforms for each of the three AKT genes, only the mRNA transcripts are different, and all transcripts of a gene result in the same protein. For example, human AKT1 has six mRNA splice isoforms (208, 202, 214, 201, 203, 211) which differ in their 5' or 3' untranslated region (UTR) but all result in the same protein. Although these UTR differences may be important for mRNA translation or localization, the protein is the same. Ensembl describes four other AKT1 splice variants (207, 213, 215, 209), which are shorter peptides, but these isoforms are "derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data" (Uniprot). In addition, these isoforms have no CCDS code and therefore may not even exist. The CCDS project is a collaborative effort to identify a core set of protein coding regions that are consistently annotated and of high quality, so isoforms lacking such a code are not considered high-quality and may not be biologically relevant. In mice, the Akt1 gene has one isoform that is confirmed (201), while the other shorter peptides (205, 208, 206) are "derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data" (Uniprot). The Akt2 gene has four splice isoforms (205, 204, 201, 214) that differ in their 5' or 3' UTR but result in the same protein. The other Akt2 splice isoforms are derived from an Ensembl automatic analysis pipeline but not verified. Only the Akt3 gene has a small difference in the last exon, where the Serine 472 phospho-site is found for the main isoforms 202 and 203, while the other isoform 201 has a different C-terminal. However, the 201 isoform has no CCDS code, suggesting it may not be a high-quality transcript. As with Akt1 and Akt2, all other Akt3 isoforms are predicted but not verified. Considering this information, we do not think the manuscript will benefit from describing mRNA splice variants because those verified for an Akt gene lead to the same protein and the focus of our study is the function of the three AKT protein isoforms in synaptic plasticity, not where the mRNA is localized or to what degree it is translated.

We had shared the same concern as the reviewer about the specificity of our reagents, which is why we used more than one AKT inhibitor in addition to genetic approaches. We also included staining in knockout samples to confirm specificity of our AKT antibodies. Although the exact epitope of these antibodies was confidential, we could retrieve information about the central peptide used for each antibody. To the best of our knowledge, these epitopes would be present in all Akt splice variants. Therefore, isoforms of each Akt gene (should they exist) would be recognized by our molecular tools. Our western results reveal single bands for both phospho- and total AKT proteins, consistent with the notion that each Akt gene generates one protein isoform. However, to address the reviewer's concern, we have added epitope information to the Materials and methods section.

> 2\) The differential expression of the three genes shown using immunolabelling in [Figure 1](#fig1){ref-type="fig"} appears to describe differential expression, with Akt2 showing most differences to Akt1 and 3. An inspection of expression data in the Allen References Atlas shows Akt1,2 and 3 are expressed in all principal neurons, but Ak2 is at lower levels than either Akt1 and 3. Inspection of single-cell transcriptome data (Zeisel et al.,1934) shows that all three genes are expressed in many cell types in the hippocampus. The authors argue that the Cre lines (Supplementary [Figure 1](#fig1){ref-type="fig"}) show evidence that Akt2 is not expressed, however these blots are overexposed (and not quantified) and the lack of reduction in Cre lines will have limited sensitivity (I doubt if it would detect a 20% reduction). Thus, I would suggest the authors caution their statements \"that Akt2 is not expressed in hippocampal neurons\" (and cite these other sources of expression data) and that \"Akt2 is specifically expressed in astrocytes\". The authors could describe them as enriched in the particular cells.

We appreciate the reviewer's caution, but we have tested many different AKT2 antibodies, of which most were not specific (showing staining in the Akt2 KO). Once we found an antibody that was specific, we were also initially surprised that the immunostaining for AKT2 showed high expression in astrocytes only. That is why we proceeded with experiments to target AKT2 selectively using Cre-mediated removal. We were also aware that the Allen Brain Atlas showed Akt2 transcripts in most cells. However, this is mRNA expression data, and mRNA that are produced do not necessarily get translated into protein. Ironically, the Zeisel et al. study cited by the reviewer reports the presence of *only* Akt2 in astrocytes and not the other isoforms, which is in fact consistent with our data (See Zeisel et al., Supplementary table S1).

Although our western blot data were collected in the linear range of detection, we have replaced the AKT2 images with lower exposures and quantified the signals to address the reviewer's concern. In addition, we added new AKT2 removal data using Nestin-driven Cre. Nestin is expressed early during embryogenesis in neural progenitor cells that become astrocytes and neurons. We found that Nestin-Cre mediated complete abolishment of AKT2 expression in the hippocampus ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), whereas neuron-specific CamkIIa-Cre or NSE-Cre did not appear to remove any AKT2 protein, supporting our idea that AKT2 is expressed specifically in astrocytes. However, because we cannot rule out trace amounts of AKT2 in neurons, we have softened our conclusion to say, "our data suggests that AKT2 is not expressed in hippocampal neurons but is mainly expressed in astrocytes" and have included discussion of other AKT expression data.

> 3\) Characterization of Akt inhibitors. Here the authors incubate brain slices with two different inhibitors and measure \"the phosphorylation of Akt\". Surely, it's important to measure the phosphorylation of each individual Akt isoform? This could be achieved by immunoprecipitation of each form followed by phosphoAKT blotting. Have these inhibitors been tested on Akt1, 2 and 3?

These inhibitors have been validated and studied previously and their pharmacological effects on each isoform have been tested (MK 2206: Akt~1/2~/3 with IC50 8/12/65 nM (1); AZD5363 Akt~1/2~/3 with IC50 3/8/8 nM (2). Our own independent data in brain slices to determine what dose to use verified the effects of these AKT inhibitors ([Figure 3](#fig3){ref-type="fig"} and [Figure 3figure supplement 1](#fig3s1){ref-type="fig"}). However, as the reviewer suggested, we have now added data showing the effect of both inhibitors on the phosphorylation status of each isoform ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In agreement with our pan-AKT results, AZD5363 incubation hyperphosphorylates all AKT isoforms while MK2206 results in reduced phosphorylation of all AKT isoforms.

> 4\) The authors say that AZD inhibitor increases pAKT S473, however the blot in [Figure 3A](#fig3){ref-type="fig"} is not convincing (the 30 and 100micM bands look the same as vehicle).

We apologize for the selected image and in response to this critique, we replaced the blot with a more representative image.

> 5\) The dissociation between the dose-dependent effects of MK and AZD on pAKTS473 and pGSK3bS9 is confusing. Why do both drugs inhibit pGSK3bS9 when MK blocks pAKTS473 and AZD increases pAKTS473? The authors refer to a paper (Okuzumiet al., 2009) that describes an interesting phenomenon of \"inhibitor hijacking\" that may be relevant. The original paper does not describe this effect on the different Akt proteins and the experiments suggested in point 3 would also address this.

We apologize that this was not presented clearly in the original manuscript. Please see our response to point 3 as well as our response to point 1 from the first reviewer, who was similarly confused by the paradoxical effect of the two inhibitors on phosphorylation of AKT.

> 6\) They decide to use the inhibitors at 30micM. This is a very high dose, especially when the MK drug strongly inhibits pAKTS473 at 10micM. ATP-competitive inhibitors are notorious for the poor specificity between families of kinases and it is typical to test the potential for non-specific inhibition of kinases. Using similar phospho-blots as in [Figure 3](#fig3){ref-type="fig"}, the authors could confirm that the doses they use are not interfering with other kinases that are known to interfere with LTP.

We understand the concern, which is noteworthy for all pharmacological studies. For this reason, our study also included genetic removal of AKT activity, although this approach carries its own caveats. Together however, the two approaches allow us to generate converging evidence in support of our conclusions. The congruent findings from our pharmacological and genetic studies strongly suggest that we were not observing non-specific effects of either approach. In addition, previous studies have used the AKT inhibitors at higher concentrations and longer durations than our study. For example, studies have reported inhibition of AKT by \~1-3 µM AZD applied up to 36 h on cells grown in a monolayer (5, 6) but in vivo application required \~69 mM for an adult mouse (200 mg/kg) (6). For MK2206, in vitro doses that have been used range between 1-20 µM for 2-72 h for cell monolayers (7-9) while in vivo application required \~75 mM for an adult mouse (240 mg/kg) (1). The brain slices that are used in our study are 400 µm thick, consisting of multiple cell layers, and treated for a short amount of time (30 min). Therefore, we disagree that 30 µM is a high dose, especially as it resulted in similar effects as genetic AKT removal. Furthermore, this was the *minimum* dose required to block substrate activation. Using less would have left incomplete AKT blockade, confounding interpretation of our results. Finally, we have tested phosphorylation of PDK in response to reviewer 1, but the results also apply here, showing that the inhibitor doses are not interfering with at least one other kinase. To more extensively address the question of potential off-target effects, an unbiased kinome screen using a mass spec approach would be required, which is well beyond the scope of this study.

> 7\) [Figure 4](#fig4){ref-type="fig"}. L-LTP inhibition. [Figure 4A and B](#fig4){ref-type="fig"} show the effects of the two inhibitors and from about 50\' the drug-treated slices show a decremental LTP. In Supplementary [Figure 2](#fig2){ref-type="fig"}, the effect of the inhibitors on the baseline is only recorded for 30\'. An important control that is missing is to record baseline for the same duration as the L-LTP experiments (200+ minutes). In the absence of this it is not possible to claim that \"activity of AKT is required to sustain long-lasting LTP\".

Although the L-LTP impairment in *Akt1* KO slices supports our inhibitor results, we performed longer baseline recordings following inhibitor treatment at the reviewer's request. We found no effect of AZD or MK on baseline recordings for as long as 90 min post-AKT inhibitor incubation ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

> 8\) L-LTP experiment are technically very demanding and it is very easy to obtain decremental L-LTP simply as a result of poor health of the slice. To control for this, it is standard practice to perform 2-pathway experiments.

We respectfully disagree that 2-pathway experiments are standard practice. L-LTP induced by high frequency stimulation is a well-established paradigm, for which 2-pathway experiments in the early days have confirmed that changes in synaptic plasticity are a phenomenon that occurs only after stimulation of a specific pathway. Most studies in mouse hippocampal slices have since not included 2-pathway experiments. Additionally, the reviewer seems to suggest that our results are due to poor health of Akt1 KO slices and AZD- and MK-treated slices only in the context of L-LTP and mGluR-LTD experiments; we do not believe this is a fair assessment. However, to address this critique, we have performed the baseline stability experiments in which slices were incubated with the inhibitors for extended periods of time (see point 7). These results show that (1) we can produce slices healthy enough to maintain stable baselines and (2) the inhibitors themselves do not reduce baseline fEPSP responses.

> 9\) Since AKT inhibitors reduced L-LTP and pGSK3bS9, then it might be expected that Akt1-knockouts would also show reduced pGSK3bS9. But in [Figure 6A](#fig6){ref-type="fig"}, apparently, this is not the case. Another dissociation is the reduction in pGSK3bS9 seen in Akt3 KO mice, which show normal L-LTP. This is confusing and important (the doses of the drugs were chosen on the basis that they inhibit pGSK3bS9).

We agree that the GSK3β results and their relationship to L-LTP are complicated, but these dissociations are the essence of our study. We had hoped to reveal signaling mechanisms linked specifically to different AKT isoforms and it appears GSK3β is one of them. GSK3β is a well-known and validated AKT target whose activity is blocked when it is phosphorylated by AKT (unphosphorylated GSK3β is the active form) (10) and was therefore chosen to validate our drug concentration. While it would have been more convenient for our study if Akt1 KO also led to reduced pGSKβ levels as with the AKT inhibitors, the data are reproducibly what we have presented. In Akt1 KO hippocampal tissue, pGSK3β levels are normal whereas in Akt3 KO tissue, pGSK3β is reduced (GSK3β is more active). We think the simplest explanation for these results is that specific AKT isoforms have preferences for certain targets, but other isoforms may be able to compensate. Thus, our results may suggest that the AKT3 isoform is specifically important for regulating pGSK3β, but reduced pGSK3β does not necessarily result in impaired L-LTP. Previously, it was found that L-LTP results in increased pGSK3β (less active GSK3β) (11). Therefore, it is possible that the presence of AKT inhibitors prevented GSK3β from being modified, resulting in impaired L-LTP. On the other hand, that GSK3β is more active in Akt3 KO yet L-LTP is not affected suggests either that AKT1 could compensate for AKT3 loss or that pGSK3β is not the mechanism mediating impaired L-LTP ([Figure 5](#fig5){ref-type="fig"}). Indeed, the revised manuscript now includes data on the phosphorylation of TSC2 ([Figure 8F](#fig8){ref-type="fig"}) to show that the inhibitors affect other downstream AKT targets as well, which justifies our drug concentration but also suggests that several other AKT mechanisms besides GSK3β regulation could underlie L-LTP. We agree with the reviewer that these are important points, so we have expanded discussion in the manuscript to help with clarity and interpretation of these results.

> 10\) [Figure 5](#fig5){ref-type="fig"}. Are statistics for slices or mice?

We apologize for the oversight and have clarified this section.

> 11\) [Figure 7](#fig7){ref-type="fig"}, mGluR-LTD, would also benefit from 2-pathway experiments (they also exceed the 30 min baseline in the control Supplementary [Figure 2](#fig2){ref-type="fig"}.

Please see point 7. As discussed also for point 8, we respectfully disagree that 2-pathway experiments should be performed, especially in the case of mGluR-LTD induced by DHPG, which is applied to the bath.

> 12\) The discrepancy between the results of LY294002 on mGluR-LTD is concerning. The original paper (Hou and Klann, 2004) showed they could reproduce the result with wortmannin. They also used an inactive structural analogue (LY294002), which had no effect. Given the controversial nature of this result, the authors should try these two other controls.

Although the 2004 paper indeed aimed to address the role of AKT in mGluR-LTD, it did not directly block AKT activity or use genetic animal models to confirm the results. Instead, the role of AKT was *inferred* from upstream inactivation of PI3K, whereas our study *directly* targets AKT using pharmacological and genetic approaches. Our results were unexpected based on the 2004 paper but not inconceivable because upstream manipulations can alter other pathways parallel to AKT signaling that lead to mGluR-LTD, which our study aimed to dissect by directly assessing AKT activity. Using three different compounds to inhibit AKT activity and a neuron-specific AKT1/3 double mutant mouse, we consistently found enhanced DHPG-induced mGluR-LTD. We did not perform mGluR-LTD experiments with wortmannin or the inactive analogue of LY294002 because the focus of our study was downstream and not upstream of AKT. We agree with the reviewer that the conflicting LY294002 results from the 2004 study and ours is concerning, but the preponderance of data suggest AKT activity is a brake on mGluR-LTD. On balance, we think the strength of our tools (multiple AKT inhibitors and genetic AKT removal) provides strong support for our conclusions, despite potential controversies generated here. We hope in the future that another group can independently confirm our results so that the role of AKT in this form of synaptic plasticity can be better clarified.

> 13\) [Figure 8](#fig8){ref-type="fig"}, double mutant mice. This is a very nice line of investigation, especially since there is overlap of expression in Akt1 and Akt3. I am very surprised the authors have not performed the L-LTP experiment (and protein synthesis, and phosoph blots) to see if the partial effect on L-LTP in Akt1 kos is not further reduced in the double mutants.

We enthusiastically agree with the reviewer that this would be a very exciting line of investigation, and we are planning to do these experiments in a follow-up paper. However, as we explained for reviewer 1, since these mutant mice are difficult to generate, we chose to use our available double mutant mice to better understand the signaling mechanisms behind enhanced mGluR-LTD after AKT blockade for the current study. In the future, we will investigate these mice in greater detail.

> Reviewer \#3:
>
> The is a solid paper with important new findings on Akt-isoform specific localization, signaling, and function in the hippocampus. The authors have effectively combined knockouts and conditional gene deletion strategies with pharmacology. The results are clear and the story is compelling and novel. Akt1, but not Akt3, supports activity-induced protein synthesis in L-LTP. Akt1 works in concert with Akt3 to inhibit mGluR-LTD, which is a completely unanticipated but well-documented finding. The article is well-written and the controversial findings, implications, and future directions are all discussed. I have only minor comments (below).
>
> 1\) From the staining shown in [Figure 1](#fig1){ref-type="fig"}., it looks like Akt1 and Akt3 are expressed in the neuropil (synaptic/dendritic). The enzymes are not exclusively somatic. The authors should comment on this.
>
> The synaptic/dendritic localization of Akt1 and Akt3 is an extremely important issue in view of the role of dendritic protein synthesis in synaptic maintenance and plasticity. PI3K/Akt signaling to mTOR has been shown to increase dendritic translation in CA1 by many labs. The authors mention the need for studies on localization but should spell out the need for work on Akt isoform signaling in local protein synthesis.

At the reviewer's suggestion, we have addressed these points in the Discussion section.

> 2\) [Figure 1](#fig1){ref-type="fig"}. There appears to be a gap in Akt3 staining in the CA1 region. Is this representative or an artefact? This segment does not seem to correspond to CA2, but there is a lot of interest in CA2 recently. The authors could comment on the distribution of Akt in CA2.

It may seem like an artefact but is representative of most of our AKT3 staining images in the WT hippocampus. We have included a different AKT3 staining image here as another example for the reviewer. We have also commented on AKT distribution in CA2 in the revised manuscript, as the reviewer suggested.
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> 3\) The electrophysiology is from CA1. The authors should state in subsection "Akt1 deletion results in impaired protein synthesis after L-LTP induction"and the first paragraph of the Discussion section (and elsewhere, if applicable) that the findings on L-LTP/mGluR-LTD are from CA1.

We have added this detail to the first paragraph of the Discussion section and in other places of the text.

> 4\) Akt1 and Akt3 are shown to have different roles in protein synthesis, and there appears to be a differential distribution of the enzymes in CA1, CA3, and DG. It is notable in this context that rapamcyin blocks L-LTP and CA1 but does not affect L-LTP in the DG (Panja et al., 2009, 2014). The regional differences in L-LTP and translation might be related to differential activation of Akt isoforms.

This is an excellent point and we have included it in our Discussion section.
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